Antibody molecules

Abstract

There remains a need in the art for additional molecules that can target PD-L1 and find use in cancer therapy. [Solution] An antibody molecule or an antigen-binding fragment thereof that can specifically bind to PD-L1. [Selected Figure] Figure 1

Description

[Technical field]

[0001] Technical Field The present invention relates to antibodies and antigen-binding fragments thereof that bind to Programmed Death Ligand 1 (PD-L1). The antibodies or antigen-binding fragments thereof comprise a CDR-based antigen-binding site of PD-L1. The antibodies or antigen-binding fragments thereof of the invention may find use, for example, in cancer therapy. [Background technology]

[0002] 2. Background of the Invention Programmed cell death 1 (PD-1) is a cell surface receptor and its ligands PD-L1 (CD274, B7-H1) and PD-L2 (B7-DC) deliver inhibitory signals that regulate the balance of T cell activation, tolerance, and immunopathology. PD-L1 is transiently expressed on all immune cells and some tumor cells.

[0003] PD-L1 is a type I transmembrane protein with two Ig-like domains in the extracellular region, a transmembrane domain, and a short cytoplasmic domain. The complete human PD-L1 (hPD-L1) sequence can be found under GENBANK® accession number Q9NZQ7. There are no known signaling motifs in the cytoplasmic domain, suggesting that there is no signaling by PD-L1 upon interaction of the ligand with its receptor. PD-L1 has a molecular weight of 40 kDa (290 amino acids) and is encoded by the CD274 gene on human chromosome 9 and mouse chromosome 19. PD-L1 is a member of the B7 protein family and shares approximately 20% amino acid sequence identity with B7.1 and B7.2. Human PD-L1 shares 70% and 93% amino acid identity with the mouse and cynomolgus orthologues of PD-L1, respectively.

[0004] Human PD-L1 binds to its receptor PD-1 with an affinity (KD) of 770 nM. PD-1 is expressed on activated T cells, B cells, and myeloid cells and regulates the activation or inhibition of cellular immune responses. When PD-L1 binds to PD-1, an inhibitory signal is delivered, reducing cytokine production and suppressing T cell proliferation. As a result, PD-L1 expression by cells can mediate protection against cytotoxic T lymphocyte (CTL) killing, a regulatory mechanism that dampens chronic immune responses during viral infections. Cancer, as a chronic and proinflammatory disease, subverts this immune protective pathway through upregulation of PD-L1 expression to evade the host immune response. In active immune responses, IFNγ also upregulates the expression of PD-L1. PD-L1 also mediates immune suppression through its interaction with another protein, B7.1 (also known as CD80), blocking its ability to deliver one of the secondary signals of T cell activation through CD28. Regarding PD-L1 expression on tumor cells and its association with B7.1, the relevance of this specific interaction in tumor immune resistance is still unclear.

[0005] PD-L1 expression has been shown in a wide variety of solid tumors. Of 654 samples examined in one study, 89 (14%) were PD-L1 positive (frequency ≥5%), spanning 19 tumors from different sites. The highest PD-L1 positivity frequencies were found in head and neck (17 / 54; 31%), cervix (10 / 34; 29%), carcinoma of unknown primary (CUP; 8 / 29; 28%), glioblastoma multiforme (GBM; 5 / 20; 25%), bladder (8 / 37; 21%), esophagus (16 / 80; 20%), triple-negative (TN) breast (6 / 33; 18%), and hepatocellular carcinoma (6 / 41; 15%) (Grosso et al., 2013). Tumor-associated expression of PD-L1 has been shown to confer immune resistance and may protect tumor cells from T cell-mediated apoptosis.

[0006] Therapies targeting PD-L1 have shown good results in in vivo studies in mice. In the B16 mouse model of melanoma, treatment with anti-PD-L1 therapy combined with either GVAX or FVAX vaccination strategies resulted in significant benefits in both survival (30 days in the control group vs. 52 days in the PD-L1-treated group) and the proportion of tumor-free (5%) animals at the end of the study (Curran et al., 2010). Anti-PD-L1 therapy has also been used to study the mechanisms of immune suppression in the P815 mouse mastoma model. P815 cells injected into mice normally induce a strong immune response, leading to their rejection. When PD-L1 is expressed on P815 cells, these cells escape immune attack, which can be abrogated by administration of anti-PD-L1 antibodies (Iwai et al., 2002). It is clear that targeting the PD-1 / PD-L1 axis in immunogenic human cancers (Herbst et al., 2014) confers a survival advantage through stimulation of anti-cancer immune responses (Wolchok et al., 2013; Larkin et al., 2015).

[0007] Atezolizumab (MPDL3280A, RG7466, TECENTRIQ™) is a humanized IgG1 antibody that binds to PD-L1. It is in clinical trials as monotherapy and in combination with other biologic and / or small molecule therapies for the treatment of solid tumors, including colorectal cancer, breast cancer, non-small cell lung cancer, bladder cancer, and renal cell carcinoma. Treatment with atezolizumab resulted in objective response rates (ORR) of 23% in NSCLC, 36% in melanoma, 33% in bladder, 14% in RCC, and 13% in head and neck cancer (Herbst et al., 2014; Powles et al., 2014).

[0008] In May 2016, the FDA granted accelerated approval to atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy, but a confirmatory trial failed to meet its primary endpoint of overall survival. In October 2016, the FDA approved atezolizumab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations must have progressed on FDA-approved therapy for these aberrations prior to receiving atezolizumab. Atezolizumab in combination with Avastin and standard chemotherapy for some patients with lung cancer is under priority review by the FDA, with a decision expected by September 5, 2018. The most common adverse reactions reported in clinical trials of atezolizumab were fatigue, loss of appetite, nausea, and infections, with urinary tract infections being the most common serious adverse reaction.

[0009] Avelumab (MSB0010718C, BAVENCIO™) is a fully human IgG1 antibody that binds to PD-L1 and is undergoing clinical trials in a number of cancers, including bladder, gastric, head and neck, mesothelioma, non-small cell lung, ovarian, renal and Merkel cell carcinoma. Avelumab received orphan drug designation from the European Medicines Agency (EMA) for the treatment of gastric cancer in January 2017. In 2017, the FDA and EMA approved avelumab for Merkel cell carcinoma (aggressive skin cancer) in adult and pediatric patients aged 12 years and older. Approval was based on data from an open-label, single-arm, multicenter clinical trial (JAVELIN Merkel 200 trial). All patients had histologically confirmed metastatic MCC with disease progression during or after chemotherapy administered for metastatic disease. The overall response rate (ORR) was assessed by an independent review committee according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The ORR was 33% with a complete response rate of 11% and a partial response rate of 22% (95% confidence interval [CI]: 23.3, 43.8). Among the 29 responding patients, response duration ranged from 2.8 to 23.3+ months, with 86% of responses lasting 6 months or longer. Responses were observed in patients regardless of PD-L1 tumor expression or the presence of Merkel cell polyomavirus. Safety data were evaluated in 1738 patients. The most common serious adverse reactions to avelumab were immune-mediated adverse reactions (pneumonitis, hepatitis, colitis, adrenal insufficiency, hypo- and hyperthyroidism, diabetes, and nephritis) and life-threatening infusion reactions. Among the 88 patients enrolled in the JAVELIN Merkel 200 trial, the most common adverse reactions were fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reactions, rash, decreased appetite, and peripheral edema. Serious adverse reactions occurring in one or more patients in the study were acute kidney injury, anemia, abdominal pain, ileus, asthenia, and cellulitis.

[0010] Durvalumab (MEDI4736, IMFINZI™) is a human IgG1 antibody that binds to PD-L1 and is being tested in clinical trials as a single agent or in combination with tremelimumab in non-small cell lung cancer, head and neck squamous cell carcinoma, bladder cancer, pancreatic cancer, and with other biologics and small molecules in trials in additional solid tumors such as gastric cancer, melanoma, and unresectable hepatocellular carcinoma.

[0011] Durvalumab is approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression on or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

[0012] Phase 1B clinical trials of durvalumab and tremelimumab have shown some activity in non-small cell lung cancer (NSCLC). However, in July 2017, AstraZeneca announced that a Phase III trial of durvalumab in combination with tremelimumab as first-line treatment for NSCLC failed to meet the primary endpoint of progression-free survival.

[0013] Early results from a Phase I study combining durvalumab with gefitinib in patients with lung cancer were reported as "promising." A Phase 1 clinical trial using durvalumab and a TLR7 / 8 agonist (MEDI 9197) in solid tumors is ongoing. A Phase 1b / 2a study combining durvalumab with an HPV DNA vaccine (MEDI 0457) in patients with HPV-related recurrent / metastatic head and neck cancer is ongoing.

[0014] In November 2017, the double-blind, phase 3 AstraZeneca PACIFIC clinical trial reported the efficacy of durvalumab in the treatment of stage III non-small cell lung cancer. A cohort of 709 patients with stage III NSCLC whose disease had not progressed after two or more cycles of platinum-based chemotherapy were randomly assigned to receive durvalumab or placebo as consolidation therapy for lung cancer. Durvalumab increased median progression-free survival from 5.6 months (placebo) to 16.8 months (durvalumab). The 12-month progression-free survival rate increased from 35.3% (placebo) to 55.9% (durvalumab), and the 18-month progression-free survival rate increased from 27.0% (placebo) to 44.2% (durvalumab). The median time to death or distant metastasis increased from 14.6 months (placebo) to 23.2 months (durvalumab), but the incidence of extreme side effects also increased from 26.1% of patients (placebo) to 29.9% of patients (durvalumab).

[0015] Adverse reactions were reported after exposure to durvalumab in 182 patients with locally advanced or metastatic urothelial carcinoma whose disease had progressed during or after one standard platinum-based regimen. Patients received durvalumab 10 mg / kg by intravenous infusion every 2 weeks. The median duration of exposure was 10.2 weeks (range: 0.14, 52.4). Thirty-one percent of patients had a delay or interruption of the drug due to adverse reactions. The most common adverse reactions (>2%) were hepatic injury (4.9%), urinary tract infection (3.3%), acute kidney injury injury (3.3%), and musculoskeletal pain (2.7%). The most common adverse reactions (≥15%) were fatigue (39%), musculoskeletal pain (24%), constipation (21%), decreased appetite (19%), nausea (16%), peripheral edema (15%), and urinary tract infection (15%). The most common grade 3 or 4 adverse reactions (≥3%) were fatigue, urinary tract infection, musculoskeletal pain, abdominal pain, dehydration, and general physical health deterioration. Eight patients (4.4%) treated with durvalumab experienced grade 5 adverse events: cardiopulmonary arrest, general physical health deterioration, sepsis, intestinal obstruction, pneumonia, or immune-mediated hepatitis. An additional three patients had experienced infection and disease progression at the time of death. Durvalumab was discontinued due to adverse reactions in 3.3% of patients. Serious adverse reactions occurred in 46% of patients. The most frequent serious adverse reactions (>2%) were acute kidney injury (4.9%), urinary tract infection (4.4%), musculoskeletal pain (4.4%), hepatic impairment (3.3%), general health deterioration (3.3%), sepsis, abdominal pain, and fever / tumor-related fever (2.7% each). Immune-mediated adverse reactions requiring systemic corticosteroids or hormone replacement therapy occurred in 8.2% (15 / 182) of patients, including 5.5% (10 / 182) of patients requiring systemic corticosteroid therapy and 2.7% (5 / 182) of patients requiring hormone replacement therapy alone. Seven patients (3.8%) received oral prednisone equivalent to >40 mg daily for immune-mediated adverse reactions.

[0016] Additional anti-PD-L1 antibodies, including BMS-936559, are being tested in clinical trials, and others are in preclinical trials.

[0017] WO 2013 / 181634 (Sorrento Therapeutics) describes PD-L1 antibodies. The only antibody disclosed, "SH1E2" (SEQ ID NOs: 147 / 148 of the application), is said to show improved T cell activation, as measured by the percentage of CD25 positive cells, when compared to the PD-L1 antibodies 10A5 and YW234.55S70 disclosed in the art.

[0018] Infectious diseases show many similarities with oncology. It is believed that the role of PD-L1 in immune regulation may be exploited to maximize the immune response against pathogens. Immunomodulation in infectious diseases is an emerging field of medicine, and early reviews suggest that PD-L1 blockade may improve the biological response to infection, manage immune-mediated clearance, and generate long-term immunity, particularly by helping to counter T cell exhaustion (Wykes and Lewin, 2017). Thus, there remains a need in the art for additional molecules that can target PD-L1 and find application in the treatment of infectious diseases.

[0019] Antibodies that target PD-L1 may also be useful in treating conditions associated with inflammation, such as vascular inflammation and stroke.

[0020] Although there are various anti-PD-L1 therapeutic agents in development, current data indicates that overall treatment with existing anti-PD-L1 monotherapy results in responses in less than 50% of cancer patients. The extent and severity of reported adverse reactions vary between antibodies in clinical trials. To increase the objective response rate (ORR) and / or reduce adverse effects, anti-PD-L1 antibodies may be combined with other biologics, such as antibodies against other checkpoint regulators, as well as small molecule therapies and other immune system activation approaches, such as tumor vaccines.

[0021] Thus, there remains a need in the art for additional molecules that can target PD-L1 and find use in cancer therapy. Summary of the Invention [Means for solving the problem]

[0022] Description of the invention The inventors prepared anti-PD-L1 antibodies by screening a phage library, followed by mutagenesis, screening, selection, and light chain shuffling, and isolated anti-PD-L1 antibodies with affinity for PD-L1 and activity in T cell activation assays.

[0023] Further rounds of mutagenesis, screening and selection were performed to remove potential sites of post-translational modifications and to improve the biophysical properties of the selected antibodies.

[0024] The above approach allowed the identification of anti-PD-L1 antibodies that exhibit excellent binding to PD-L1 and activity in T cell activation assays. Based on these characteristics, the antibodies of the invention are expected to find use in the treatment of human cancers, as well as infectious and inflammatory diseases, via inhibition of PD-L1.

[0025] The antibodies of the invention were also shown to have high affinity for cynomolgus monkey PD-L1, comparable to their affinity for human PD-L1.The antibodies of the invention also showed measurable affinity for mouse PD-L1.

[0026] Furthermore, antibodies against PD-L1 have been shown to have relatively high melting temperatures, which is expected to improve stability, beneficial for antibody production and storage.

[0027] The present invention provides: 1. An antibody or antigen-binding fragment thereof capable of specifically binding to PD-L1, comprising a variable heavy chain (VH) domain comprising heavy chain complementarity determining regions (CDRs): HCDR1, HCRD2, and HCDR3, characterized in that the amino acid sequence of HCDR1 (amino acids 31 to 35) is SYGIS (SEQ ID NO:1); the amino acid sequence of HCDR2 is WISAYX1X2X3X4NYAQKLQG (SEQ ID NO:2); and the amino acid sequence of HCDR3 is DLFPTIFGVSYYYY (SEQ ID NO:3); where X1 is S or N or G; X2 is G or S; X3 is or G, N or S; and X4 is T or A, and the sequences are defined according to the Kabat nomenclature.

[0028] 2. The antibody or antigen-binding fragment thereof according to item 1, characterized in that the amino acid sequence of HCDR1 (amino acids 31 to 35) is SYGIS (SEQ ID NO: 1); the amino acid sequence of HCDR2 is WISAYX1X2X3X4NYAQKLQG (SEQ ID NO: 2); and the amino acid sequence of HCDR3 is DLFPTIFGVSYYYY (SEQ ID NO: 3); wherein X1 is S or N; X2 is G or S; X3 is G or N; and X4 is T, and the sequences are defined according to the Kabat nomenclature.

[0029] 3. The antibody or antigen-binding fragment thereof according to item 1 or 2, wherein the amino acid at position 28 preceding HCDR1 is P or T.

[0030] 4. The antibody or antigen-binding fragment thereof according to any one of items 1 to 3, wherein the sequence X1X2X3X4 (SEQ ID NO: 4) (residues 54 to 57) of HCDR2 is selected from SGGT (SEQ ID NO: 5), NSNT (SEQ ID NO: 6), GGST (SEQ ID NO: 7) and SGNA (SEQ ID NO: 8).

[0031] 5. The antibody or antigen-binding fragment thereof according to any one of items 1 to 4, wherein the residue at position 28 (Kabat nomenclature) of HCDR1 is P and the sequence X1X2X3X4 (SEQ ID NO: 4 (residues 54-57) of HCDR2 is SGGT (SEQ ID NO: 5).

[0032] 6. (a) the variable light chain (VL) is a kappa VL and the amino acid sequence of LCDR1 is RASQSIX5X6RLA (SEQ ID NO: 9); the amino acid sequence of LCDR2 is EASX7X8EX9 (SEQ ID NO: 10); and the amino acid sequence of LCDR3 is QQX 10 X 11 X 12 X 13 PX 14 X 15 X 16 (SEQ ID NO: 11); wherein X5 is G or S; X6 is N or G; X7 is T or N; X8 is S or L; X9 is T or S; 10 is S or A; X 11 is Y or N; X 12 is S or T; X 13 is T, W or F; X 14 is absent or R; X 15 is Y, R or V; X 16 is T or S, or (b) the VL is a lambda VL and the amino acid sequence of LCDR1 is: TGTSSDVGGYNX 17 VS (SEQ ID NO: 12); the amino acid sequence of LCDR2 is EVTNRPS (SEQ ID NO: 13); the amino acid sequence of LCDR3 is SSFKRGSTLVV (SEQ ID NO: 14); 17 is Y or S; the sequences are defined according to the Kabat nomenclature. 6. The antibody or antigen-binding fragment thereof according to any one of items 1 to 5, comprising a VL domain comprising light chain complementarity determining regions: LCDR1, LCDR2 and LCDR3,

[0033] 7. The antibody or antigen-binding fragment thereof according to item 6, wherein the VL domain is a kappa VL, the amino acid sequence of LCDR1 is RASQSIGNRLA (sequence number 15); the amino acid sequence of LCDR2 is EASTSET (sequence number 16); and the amino acid sequence of LCDR3 is QQSYSTPYT (sequence number 17).

[0034] 8. Antibodies: (a) G1AA / E12v2 of SEQ ID NOs: 1, 18, 3, 15, 16 and 17; (b) G1AA / G12v2 of SEQ ID NOs: 1, 18, 3, 19, 20 and 21; (c) G1AA / E05v2 of SEQ ID NOs: 1, 18, 3, 19, 20 and 22; (d) G1 / 887_04_E12 with SEQ ID NOs: 1, 23, 3, 15, 16 and 17; (e) G1 / 887_04_G12 of SEQ ID NOs: 1, 23, 3, 19, 20 and 21; (f) G1 / 894_08_E05 with SEQ ID NOs: 1, 23, 3, 19, 20 and 22; (g) G1 / 894_08_A05 with SEQ ID NOs: 1, 23, 3, 19, 20 and 24; (h) G1AA / lambdav3 of SEQ ID NOs: 1, 18, 3, 25, 13 and 14; (i) G1 / 280_02_G02_NS of SEQ ID NOs: 1, 23, 3, 26, 13 and 14, or (j) G1 / 280_02_G02 of SEQ ID NOs: 1, 78, 3, 26, 13 and 14; 8. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, comprising an antigen-binding site comprising the CDRs (HCDR1, HCRD2, HCDR3, LCDR1, LCDR2 and LCDR3, respectively), wherein the sequences are defined according to the Kabat nomenclature.

[0035] 9. The antigen-binding site of an antibody: (a) G1AA / E12v2 of SEQ ID NOs: 27 and 28, respectively; (b) G1AA / G12v2 of SEQ ID NOs: 29 and 30, respectively; (c) G1AA / E05v2 of SEQ ID NOs: 31 and 32, respectively; (d) G1 / 887_04_E12 with SEQ ID NOs: 33 and 34, respectively; (e) G1 / 887_04_G12 of SEQ ID NOs: 35 and 36, respectively; (f) G1 / 894_08_E05 with SEQ ID NOs: 37 and 38, respectively; (g) G1 / 894_08_A05 with SEQ ID NOs: 39 and 40, respectively; (h) G1AA / lambdav3 of SEQ ID NOs: 41 and 42, respectively; (i) G1 / 280_02_G02_NS of SEQ ID NOs: 43 and 44, respectively; or (j) G1 / 280_02_G02 of SEQ ID NOs: 45 and 46, respectively; 9. The antibody or antigen-binding fragment of any one of claims 1 to 8, comprising the VH and / or VL domains of:

[0036] 10.Antibody molecule, an antibody: (a) G1AA / E12v2 of SEQ ID NOs: 47 and 48, respectively; (b) G1AA / G12v2 of SEQ ID NOs: 49 and 50, respectively; (c) G1AA / E05v2 of SEQ ID NOs: 51 and 52, respectively; (d) G1 / 887_04_E12 with SEQ ID NOs: 53 and 54, respectively; (e) G1 / 887_04_G12 with SEQ ID NOs: 55 and 56, respectively; (f) G1 / 894_08_E05 with SEQ ID NOs: 57 and 58, respectively; (g) G1 / 894_08_A05 with SEQ ID NOs: 59 and 60, respectively; (h) G1AA / lambdav3 of SEQ ID NOs: 61 and 62, respectively; (i) G1 / 280_02_G02_NS of SEQ ID NOs: 63 and 64, respectively; or (j) G1 / 280_02_G02 of SEQ ID NOs: 65 and 66, respectively; 10. The antibody molecule of any one of claims 1 to 9, comprising a heavy chain and / or a light chain of:

[0037] 11. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 10, comprising HCDR (HCDR1, HCDR2 and HCDR3) and / or LCDR (LCDR1, LCDR2 and LCDR3); VH and / or VL; Fab; and the light chain and / or heavy chain of antibody G1AA / E12v2, G1AA / G12v2 or G1AA / E05v2.

[0038] 12. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 11, comprising HCDR (HCDR1, HCDR2 and HCDR3) and / or LCDR (LCDR1, LCDR2 and LCDR3); VH and / or VL; Fab; and the light chain and / or heavy chain of antibody G1AA / E12v2 or G1 / E12v2.

[0039] 13. The antibody or antigen-binding fragment thereof according to any one of clauses 1 to 12, wherein the VH has at least 95, 96, 97, 98 or 99% identity to the VH of an antibody selected from G1AA / E12v2 of SEQ ID NO: 27, G1AA / G12v2 of SEQ ID NO: 29, G1AA / E05v2 of SEQ ID NO: 31, G1 / 887_04_E12 of SEQ ID NO: 33, G1 / 887_04_G12 of SEQ ID NO: 35, G1 / 894_08_E05 of SEQ ID NO: 37, G1 / 894_08_A05 of SEQ ID NO: 39, G1AA / lambdav3 of SEQ ID NO: 41, G1 / 280_02_G02_NS of SEQ ID NO: 43, and G1 / 280_02_G02 of SEQ ID NO: 45.

[0040] 14. The antibody or antigen-binding fragment thereof of any one of clauses 1 to 13, wherein the antibody molecule or antigen-binding fragment binds to human PD-L1.

[0041] 15. The antibody or antigen-binding fragment thereof of any one of clauses 1 to 14, wherein the antibody molecule or antigen-binding fragment binds to cynomolgus PD-L1.

[0042] 16. The antibody or antigen-binding fragment thereof of any one of clauses 1 to 15, wherein the antibody or antigen-binding fragment binds to mouse PD-L1.

[0043] 17. The antibody or antigen-binding fragment thereof of any one of clauses 1 to 16, wherein the antibody or antigen-binding fragment has an affinity (KD) for recombinant human PD-L1 and recombinant cynomolgus PD-L1 of less than 2 nM, preferably less than 1 nM, more preferably less than 0.75 nM, and even more preferably less than 0.5 nM, as measured by SPR (e.g. Biacore).

[0044] 18. The antibody or antigen-binding fragment thereof of any one of clauses 1 to 17, wherein the antibody or antigen-binding fragment thereof enhances T cell activation as assessed in a mixed lymphocyte reaction (MLR) assay.

[0045] 19. The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen-binding fragment is a multispecific, preferably bispecific, molecule comprising at least a second antigen-binding site.

[0046] 20. The antibody or antigen-binding fragment of any one of clauses 1 to 19, wherein the antibody or antigen-binding fragment thereof comprises a second antigen-binding site located in a constant domain of the antibody or antigen-binding fragment.

[0047] 21. The second antigen-binding site is (a) a first sequence in the AB structural loop and / or a second sequence in the EF structural loop of a constant heavy domain, (b) a first sequence in the AB structural loop and a second sequence in the EF structural loop of the constant heavy domain; (c) a first sequence in the AB structural loop and / or a second sequence in the EF structural loop and / or a third sequence in the CD structural loop of the constant heavy chain domain; (d) a first sequence in the AB structural loop, a second sequence in the EF structural loop, and a third sequence in the CD structural loop of the constant heavy domain; The antibody or antigen-binding fragment thereof according to item 20,

[0048] 22. The antibody or antigen-binding fragment thereof according to clause 20 or 21, wherein the constant heavy chain domain is a CH3 domain.

[0049] 23. The antibody or antigen-binding fragment thereof of any one of clauses 1 to 22, wherein the antibody is immunoglobulin G (IgG) or an antigen-binding fragment thereof.

[0050] 24. The antibody or antigen-binding fragment thereof according to clause 23, wherein the antibody is an IgG1 or a fragment thereof, or an IgG4 or a fragment thereof.

[0051] 25. The antibody or antigen-binding fragment thereof according to clause 23 or clause 24, wherein the antibody is an IgG1 or a fragment thereof having a modified Fc region.

[0052] 26. The antibody or antigen-binding fragment thereof according to clause 24 or clause 25, wherein the antibody is an IgG1 or a fragment thereof having a modified Fc region with reduced immune effector function.

[0053] 27. The antibody or antigen-binding fragment thereof according to clause 25 or 26, wherein the modified Fc has reduced ADCC and / or CDC compared to IgG1.

[0054] 28. The antibody or antigen-binding fragment thereof of any one of clauses 25 to 27, wherein the modified Fc region comprises a LALA, LALA-PA, or LALA-PG modification.

[0055] 29. The antibody or antigen-binding fragment thereof according to any one of clauses 25 to 28, wherein the antibody is an IgG1 or antigen-binding fragment thereof comprising a LALA modification in the Fc region.

[0056] 30. The antibody or antigen-binding fragment thereof of any one of clauses 19 to 29, wherein the second antigen-binding site binds to an inhibitory checkpoint molecule, a costimulatory molecule, or a tumor-associated antigen.

[0057] According to the present invention, in the antibody or antigen-binding fragment thereof, the second antigen-binding site may bind to an inhibitory checkpoint molecule such as CTLA-4, LAG-3, TIGIT, TIM-3, VISTA, CD73, CSF-1R, KIR.B7-H3, B7-H4, 2B4, NKG2A, CD47, SIRPa, BTLA, CCR4, CD200R, or TGF beta.

[0058] According to the present invention, in the antibody or antigen-binding fragment thereof, the second antigen-binding site binds to and may be an agonist of a costimulatory molecule expressed by T cells, such as OX40, ICOS, CD40, HVEM, NKG2D, or TNFR2.

[0059] According to the present invention, in the antibody or antigen-binding fragment thereof, the second antigen-binding site may bind to a tumor-associated antigen (TAA), such as c-Met, B7-H3, B7-H4, EGFR, HER-2, EPCAM, CEACAM, FAP, VEGF, MSLN, GPC3, CD38, CD19, or CD20.

[0060] 31. The antibody or antigen-binding fragment thereof of any one of clauses 19 to 30, wherein the second antigen-binding site does not bind to OX40, inducible T cell costimulator (ICOS), or CD137.

[0061] 32. The antibody or antigen-binding fragment thereof of any one of clauses 19 to 30, wherein the second antigen-binding site does not bind to CD27 or glucocorticoid-induced TNFR-related protein (GITR).

[0062] 33. The antibody or antigen-binding fragment thereof of any one of clauses 19 to 30, wherein the second antigen-binding site does not bind to lymphocyte activation gene 3 (LAG-3).

[0063] 34. A conjugate or fusion comprising the antibody or antigen-binding fragment thereof of any one of paragraphs 1 to 33 and an immune system modulator (agonist or antagonist), a cytotoxic molecule, or a radioisotope.

[0064] 35. The antibody, antigen-binding fragment, conjugate or fusion thereof of any one of paragraphs 1 to 34, having a detectable label.

[0065] 36. A nucleic acid molecule or set of nucleic acid molecules encoding an antibody, antigen-binding fragment thereof, conjugate or fusion thereof according to any one of clauses 1 to 35.

[0066] 37. A nucleic acid molecule or set of nucleic acid molecules comprising: (a) G1AA / E12v2 or G1 / E12v2; (b) G1AA / E05v2 or G1 / E05v2; (c) G1AA / G12v2 or G1 / G12v2; (d) G1 / 887_04_E12; (e) G1 / 894_08_E05; (f) G1 / 887_04_G12; (g) G1 / 894_08_A05; (h) G1AA / lambdav3; (i) G1 / 280_02_G02_NS; or (j) G1 / 280_02_G02. 37. The nucleic acid molecule or set of nucleic acid molecules according to claim 36, comprising a cDNA sequence encoding one or more of the VH and / or VL, Fab, heavy chain and / or light chain of said nucleic acid molecule or set of nucleic acid molecules according to claim 36.

[0067] 38. A nucleic acid sequence comprising a first nucleic acid sequence and a second nucleic acid sequence, (a) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1AA / E12v2 of SEQ ID NO: 27, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1AA / E12v2 of SEQ ID NO: 28; or (b) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1AA / G12v2 of SEQ ID NO: 29, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1AA / G12v2 of SEQ ID NO: 30; or (c) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1AA / E05v2 of SEQ ID NO: 31, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1AA / E05v2 of SEQ ID NO: 32; or (d) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1 / 887_04_E12 of SEQ ID NO: 33, and the second nucleic acid sequence comprises a VL cDNA sequence of the antibody G1 / 887_04_E12 of SEQ ID NO: 34; or (e) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1 / 887_04_G12 of SEQ ID NO: 35, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1 / 887_04_G12 of SEQ ID NO: 36; or (f) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1 / 894_08_E05 of SEQ ID NO: 37, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1 / 894_08_E05 of SEQ ID NO: 38; or (g) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1 / 894_08_A05 of SEQ ID NO: 39, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1 / 894_08_A05 of SEQ ID NO: 40; or (h) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1AA / lambdav3 of SEQ ID NO: 41, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1AA / lambdav3 of SEQ ID NO: 42; or (i) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1 / 280_02_G02_NS of SEQ ID NO: 43, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1 / 280_02_G02_NS of SEQ ID NO: 44; or (i) the first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1 / 280_02_G02 of SEQ ID NO: 45, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1 / 280_02_G02 of SEQ ID NO: 46; 38. A nucleic acid molecule or set of nucleic acid molecules according to item 37.

[0068] 39. A vector or a set of vectors comprising the nucleic acid molecule or set of nucleic acid molecules of any of clauses 36 to 38.

[0069] 40. A recombinant host cell comprising a nucleic acid molecule or set of nucleic acid molecules of any of paragraphs 36 to 38, or a vector or set of vectors of paragraph 39.

[0070] 41. A method for producing an antibody, antigen-binding fragment thereof, conjugate or fusion according to any one of clauses 1 to 35, comprising culturing a recombinant host cell of clause 40 under conditions suitable for the production of the antibody, antigen-binding fragment, conjugate or fusion.

[0071] 42. The method of clause 41, further comprising isolating and / or purifying the antibody, antigen-binding fragment, conjugate or fusion.

[0072] 43. A composition (e.g., a pharmaceutical composition) comprising the antibody, antigen-binding fragment, conjugate or fusion of any one of clauses 1 to 42 and an excipient (e.g., a pharma- ceutically acceptable excipient).

[0073] 44. The antibody, antigen-binding fragment, conjugate or fusion of any one of clauses 1 to 35, or the composition of clause 43, for use in a method of treatment of the human or animal body by therapy.

[0074] 45. A method of treating a disease or disorder in a patient, comprising administering to the patient a therapeutically effective amount of an antibody, antigen-binding fragment thereof, conjugate or fusion of any one of clauses 1 to 35, or a composition of clause 43.

[0075] 46. ​​Use of an antibody, antigen-binding fragment thereof, conjugate or fusion of any one of clauses 1 to 35, or a composition of clause 43 in the manufacture of a medicament for the treatment of the human or animal body.

[0076] 47. The antibody, antigen-binding fragment thereof, conjugate or fusion of any one of clauses 1 to 35, or the composition of clause 43, for use according to clause 44 in a method of treatment comprising administering the antibody, antigen-binding fragment thereof, conjugate, fusion or composition to the human or animal body in combination with a second treatment.

[0077] 48. The method of paragraph 45 or the use of paragraph 46, wherein the method further comprises administering to the patient a therapeutically effective amount of a second treatment.

[0078] 49. The antibody, antigen-binding fragment thereof, conjugate, fusion or composition for use according to clause 47 or in the method according to clause 48, wherein the second treatment is radiotherapy, preferably targeted radiotherapy.

[0079] 50. The antibody, antigen-binding fragment, conjugate or fusion of any one of clauses 1 to 35, or the composition of clause 43, for use in a diagnostic method performed on the human or animal body, or performed in vitro on a sample from the human or animal body.

[0080] 51. A method for detecting a disease or disorder in a patient, comprising the use of an antibody, antigen-binding fragment thereof, conjugate or fusion thereof according to any one of clauses 1 to 35, or a composition according to clause 43.

[0081] 52. Use of an antibody, antigen-binding fragment thereof, conjugate or fusion according to any one of clauses 1 to 35, or a composition according to clause 43 in the manufacture of a diagnostic agent.

[0082] Treatment of various types of cancer with anti-PD-L1 or anti-PD-1 antibodies has been investigated in clinical trials and has shown promising results. These include ovarian cancer, prostate cancer, colorectal cancer, fibrosarcoma, renal cell carcinoma, melanoma (advanced and metastatic melanoma), pancreatic cancer, breast cancer, glioblastoma multiforme, lung cancer (including non-small cell lung cancer and small cell lung cancer), head and neck cancer (including head and neck squamous cell carcinoma), stomach cancer (including gastric cancer), and ovarian cancer. Cancers of the present invention include solid tumors such as bladder cancer, cervical cancer, uterine cancer (endometrial cancer, cervical cancer), vulvar cancer, testicular cancer, penile cancer, esophageal cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, Merkel cell carcinoma, mesothelioma, DNA mismatch repair deficient colorectal cancer, DNA mismatch repair deficient endometrial cancer, thyroid cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma (diffuse large B-cell lymphoma, follicular lymphoma, indolent non-Hodgkin's lymphoma, mantle cell lymphoma, etc.), leukemia (chronic lymphocytic leukemia, myeloid leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, etc.), multiple myeloma, and peripheral T-cell lymphoma. Thus, the antibodies or antigen-binding fragments thereof of the present invention may find use in the treatment of these cancers. Tumors of these cancers are known or expected to contain immune cells such as TILs that express PD-L1.

[0083] In particular, the treatment of melanoma, colorectal cancer, breast cancer, bladder cancer, renal cell carcinoma, gastric cancer, head and neck cancer (such as squamous cell carcinoma of the head and neck), mesothelioma, lung cancer (such as non-small cell lung cancer), ovarian cancer, Merkel cell carcinoma, pancreatic cancer, melanoma, and hepatocellular carcinoma with PD-L1 antibodies has been investigated in clinical trials and has shown promising results. Thus, the cancer treated using the antibodies or antigen-binding fragments thereof of the invention may be melanoma, colorectal cancer, breast cancer, bladder cancer, renal cell carcinoma, bladder cancer, gastric cancer, head and neck cancer (such as squamous cell carcinoma of the head and neck), mesothelioma, lung cancer (such as non-small cell lung cancer), ovarian cancer, Merkel cell carcinoma, pancreatic cancer, melanoma, or hepatocellular carcinoma.

[0084] Cancer may be characterized by the abnormal proliferation of malignant cancer cells. When the application refers to a particular type of cancer, such as breast cancer, it refers to the malignant transformation of the relevant tissue, in this case breast tissue. Cancer resulting from the malignant transformation of a different tissue, for example ovarian tissue, may result in metastatic lesions in another location of the body, such as the breast, but this is not the breast cancer referred to herein, but ovarian cancer.

[0085] The cancer may be a primary cancer or a secondary cancer. Thus, the antibodies or antigen-binding fragments thereof of the invention may be for use in methods of treating cancer in a patient, where the cancer is a primary tumor and / or a tumor metastasis.

[0086] The antibodies or antigen-binding fragments thereof of the present invention may also be expected to find use in the treatment of infectious diseases, such as viral, bacterial, fungal and / or parasitic infections. Preferably, the infectious disease is a viral, bacterial or fungal disease, more preferably a viral or bacterial disease, most preferably a viral disease. The infectious disease may be chronic or acute, but is preferably chronic.

[0087] Examples of viral diseases that may be treated with an antibody or antigen-binding fragment thereof according to the invention include human immunodeficiency virus (HIV), influenza virus, enterovirus, hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis A virus (HAV), hepatitis D virus (HDV), hepatitis E virus (HEV), respiratory syncytial virus (RSV), herpes viruses (such as Epstein-Barr virus, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), cytomegalovirus (CMV)), and papilloma virus infections.

[0088] Examples of bacterial diseases that can be treated with the antibodies, or antigen-binding fragments thereof, of the invention include Mycobacterium tuberculosis, Gram-negative bacteria (such as Acinetobacter, Klebisella, Enterobacter), Gram-positive bacteria (such as Clostridium difficile, Staphylococcus aureus), and Listeria (such as Listeria monocytogenes) infections.

[0089] Examples of fungal diseases that can be treated with the antibodies, or antigen-binding fragments thereof, of the invention include Aspergillus and Candida infections.

[0090] Examples of parasitic diseases that can be treated with the antibodies, or antigen-binding fragments thereof, of the invention include malaria, toxoplasma, and leishmania infections.

[0091] The antibody or antigen-binding fragment thereof according to the invention is designed to be used in a method of treatment of a patient, preferably a human patient. The antibody or antigen-binding fragment thereof of the invention is usually administered in the form of a pharmaceutical composition, which may contain at least one additional component, such as a pharma- ceutically acceptable excipient. For example, the pharmaceutical composition of the invention may contain, in addition to the antibody or antigen-binding fragment thereof, a pharma- ceutically acceptable excipient, carrier, buffer, stabilizer, or other material well known to those skilled in the art. Such materials must be non-toxic and must not interfere with the efficacy of the antibody or antigen-binding fragment thereof. The exact nature of the carrier or other material will depend on the route of administration, which may be by injection (e.g., intravenous or subcutaneous). The antibody or antigen-binding fragment thereof may be administered intravenously or subcutaneously.

[0092] Liquid pharmaceutical compositions generally include a liquid carrier, such as water or saline. For subcutaneous or intravenous injection, or injection at an affected site, the antibody or antigen-binding fragment thereof, or pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, is preferably in the form of a parenterally acceptable aqueous solution that is pyrogen-free and has suitable pH, isotonicity and stability.

[0093] The composition comprising the antibody or its antigen-binding fragment according to the present invention can be administered alone or in combination with other treatments, simultaneously or sequentially, or as a combined formulation with another therapeutic agent depending on the condition to be treated.For example, the antibody or its fragment of the present invention can be administered in combination with an existing therapeutic agent for the disease to be treated, such as cancer, as described above.For example, the antibody or its fragment of the present invention can be administered to a patient in combination with a second anti-cancer therapy, such as chemotherapy, anti-tumor vaccination (also called cancer vaccination), radiation therapy, immunotherapy, oncolytic virus, chimeric antigen receptor (CAR) T-cell therapy, or hormone therapy.

[0094] It is expected that the antibodies or fragments thereof of the present invention may act as adjuvants in anti-cancer therapies, such as chemotherapy, anti-tumor vaccination, or radiation therapy. Without wishing to be bound by theory, it is believed that administration of the antibodies or fragments thereof to a patient as part of chemotherapy, anti-tumor vaccination, or radiation therapy induces a greater immune response against the cancer-associated antigen PD-L1 than is achieved by chemotherapy, anti-tumor vaccination, or radiation therapy alone.

[0095] Thus, a method for treating cancer in a patient may comprise administering to the patient a therapeutically effective amount of an antibody or fragment thereof according to the invention in combination with a chemotherapeutic agent, an antitumor vaccine, a radionuclide, an immunotherapeutic agent, an oncolytic virus, a CAR-T cell, or a hormonal therapy agent. The chemotherapeutic agent, antitumor vaccine, radionuclide, immunotherapeutic agent, oncolytic virus, a CAR-T cell, or a hormonal therapy agent is preferably a chemotherapeutic agent, an antitumor vaccine, a radionuclide, immunotherapeutic agent, oncolytic virus, a CAR-T cell, or a hormonal therapy agent for the cancer in question, i.e. a chemotherapeutic agent, an antitumor vaccine, a radionuclide, immunotherapeutic agent, oncolytic virus, a CAR-T cell, or a hormonal therapy agent that has been shown to be effective in treating the cancer in question. The selection of a suitable chemotherapeutic agent, an antitumor vaccine, a radionuclide, immunotherapeutic agent, oncolytic virus, a CAR-T cell, or a hormonal therapy agent that has been shown to be effective against the cancer in question is well within the capabilities of a person skilled in the art.

[0096] For example, when the method comprises administering to a patient a therapeutically effective amount of an antibody or fragment thereof according to the invention in combination with a chemotherapeutic agent, the chemotherapeutic agent may be selected from the group consisting of taxanes, cytotoxic antibiotics, tyrosine kinase inhibitors, PARP inhibitors, B_RAF enzyme inhibitors, alkylating agents, platinum analogues, nucleoside analogues, thalidomide derivatives, anti-cancer chemotherapeutic agents, and the like. Taxanes include docetaxel, paclitaxel, and nab-paclitaxel; cytotoxic antibiotics include actinomycin, bleomycin, anthracyclines, doxorubicin, and valrubicin; tyrosine kinase inhibitors include sunitinib, erlotinib, gefitinib, axitinib, PLX3397, imatinib, cobemitinib, and trametinib; PARP inhibitors include pilaparib; B-Raf enzyme inhibitors include vemurafenib and dabrafenib; alkylating agents include dacarbazine, cyclophosphamide, temozolomide; platinum analogs include carboplatin, cisplatin, and oxaliplatin; nucleoside analogs include gemcitabine and azacitidine; and anti-cancer agents include fludarabine. Other chemotherapeutic agents suitable for use in the present invention include methotrexate, defactinib, entinostat, pemetrexed, capecitabine, eribulin, irinotecan, fluorouracil, and vinblastine.

[0097] Vaccination strategies for the treatment of cancer have been implemented in the clinic and have been discussed at length in the scientific literature (e.g., Rosenberg S. Development of Cancer Vaccines. ASCO Educational Book Spring:60-62 (2000)). This primarily involves strategies to stimulate the immune system to respond to various cell markers expressed by autologous or allogeneic cancer cells by using these cells as a vaccination method, both with and without granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF induces a strong response in antigen presentation and works particularly well when used in said strategies.

[0098] When the method of the invention comprises administering to a patient a therapeutically effective amount of an antibody or fragment thereof according to the invention in combination with an immunotherapeutic agent, the immunotherapeutic agent may be selected from the group consisting of a checkpoint inhibitor, an antibody that binds a costimulatory molecule, or a soluble factor (such as an antibody that binds to CTLA-4, LAG-3, TIGIT, TIM-3, VISTA, CD73, CSF-1R, KIR, OX40, CD40, HEVM, TGFB, IL-10, CSF-1, etc.) Alternatively, the immunotherapeutic agent may be a cytokine or cytokine-based therapy selected from the group consisting of one or more of IL-2, a prodrug of conjugated IL-2, GM-CSF, IL-7, IL-12, IL-9, IL-15, IL-18, IL-21, and a type I interferon.

[0099] The administration may be a "therapeutically effective amount", which is an amount sufficient to show a benefit to the patient. Such benefit may be at least an improvement of at least one symptom. Thus, "treatment" of a particular disease refers to an improvement of at least one symptom. The actual amount administered, as well as the rate and time course of administration, will depend on the nature and severity of the subject being treated, the particular patient being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the composition, the type of antibody or fragment thereof, the method of administration, the schedule of administration, and other factors known to physicians. Prescription of treatment, such as determining the dosage, is within the responsibility of general practitioners and other physicians and may depend on the severity of the symptoms and / or the progression of the disease being treated. Appropriate doses of antibodies or fragments thereof are well known in the art (Ledermann et al. (1991) Int. J. Cancer 47:659-664; and Bagshawe et al. (1991) Antibody, Immunoconjugates and Radiopharmaceuticals 4:915-922). Specific dosages as indicated herein or in the Physician's Desk Reference (2003) appropriate for the antibody or fragment thereof administered may be used. The therapeutically effective amount or appropriate dose of an antibody or fragment thereof may be determined by comparing its in vitro activity and in vivo activity in an animal model. Methods are known for extrapolating effective dosages in mice and other test animals to humans. The exact dosage depends on a number of factors, including the size and location of the area to be treated and the exact nature of the specific binding member. Treatments may be repeated daily, twice weekly, weekly, or monthly, at the discretion of the physician. Treatments may be administered before and / or after surgery and may be administered or applied directly to the anatomical site of surgical procedure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0100] Detailed Description The present invention relates to antibodies and antigen-binding fragments thereof comprising a CDR-based antigen-binding site of PD-L1. The antibodies or antigen-binding fragments thereof of the present invention may be produced by recombinant means. A "recombinant antibody" is an antibody produced by recombinantly engineered host cells. The antibodies or antigen-binding fragments thereof according to the present invention are optionally isolated or purified.

[0101] The term "PD-L1" may refer to human PD-L1, murine, particularly mouse PD-L1, and / or cynomolgus PD-L1, unless the context requires otherwise. Preferably, the term "PD-L1" refers to human PD-L1, unless the context requires otherwise.

[0102] The term "antibody molecule" describes an immunoglobulin, whether natural or partially or wholly synthetically produced. The antibody molecule may be human or humanized. The antibody molecule is preferably a monoclonal antibody molecule. Examples of antibodies are immunoglobulin isotypes such as immunoglobulin G, and their isotypic subclasses such as IgG1, IgG2, IgG3 and IgG4, and fragments thereof. The four human subclasses (IgG1, IgG2, IgG3 and IgG4) each contain different heavy chains, but they are highly homologous and differ mainly in the hinge region and the extent to which they activate the host's immune system. IgG1 and IgG4 contain two interchain disulfide bonds in the hinge region, IgG2 has four, and IgG3 has eleven interchain disulfide bonds.

[0103] As used herein, the terms "antibody" and "antibody molecule" include antibody fragments, such as Fab and scFv fragments, provided that said fragments contain the CDR-based antigen-binding site of PD-L1. Thus, unless the context requires otherwise, the terms "antibody" or "antibody molecule" as used herein are equivalent to "antibody or antigen-binding fragment thereof".

[0104] Antibodies are immunoglobulins that have the same basic structure of two heavy and two light chains forming two Fab arms. The arms contain identical domains that are connected by a flexible hinge region to the stem of the antibody, the Fc domain, giving it a classic "Y" shape. The Fab domain consists of two variable domains and two constant domains, the heavy chain has a variable heavy (VH) and a constant heavy 1 (CH1) domain, and the light chain has a variable light (VL) and a constant light (CL) domain. The two variable domains (VH and VL) form a variable fragment (Fv), which provides the CDR-based antigen specificity of the antibody, while the constant domains (CH1 and VL) serve as the structural framework. Each variable domain contains three hypervariable loops known as complementarity determining regions (CDRs). In each of VH and VL, the three CDRs (CDR1, CDR2, and CDR3) are flanked by four less variable framework (FR) regions (FR1, FW2, FW3, and FW4), resulting in the structure FW1-CDR1-FW2-CDR2-FW3-CDR3-FW4. The CDRs provide specific antigen recognition sites on the surface of the antibody.

[0105] Both Kabat and ImMunoGeneTics (IMGT) numbering nomenclature are used herein. Generally, unless otherwise indicated (explicitly or by context), amino acid residues are numbered herein according to the Kabat numbering scheme (Kabat et al., 1991). In instances where IMGT numbering is used, amino acid residues are numbered herein according to the ImMunoGeneTics (IMGT) numbering scheme. The IMGT numbering scheme is described in Lefranc et al., 2005.

[0106] When sequences are defined by the IMGT nomenclature, the present invention provides: 1A. An antibody or antigen-binding fragment thereof capable of specifically binding to PD-L1, comprising a variable heavy (VH) domain comprising CDRs: HCDR1, HCRD2 and HCDR3, each flanked by framework (FW) regions, characterized in that the amino acid sequence of HCDR1 is GYX1FTSYG (SEQ ID NO:67); the amino acid sequence of HCDR2 is ISAYX2X3X4X5 (SEQ ID NO:68); and the amino acid sequence of HCDR3 is ARDLFPTIFGVSYYYY (SEQ ID NO:69); wherein X1 is P or T; X2 is S, N or G, preferably S or N; X3 is G or S; X4 is G, N or S, preferably G or N; and X5 is T or A, preferably T, and the sequences are defined according to the ImMunoGeneTics (IMGT) nomenclature.

[0107] 2A. The antibody or antigen-binding fragment thereof according to item 1A, wherein the sequence X2X3X4X5 (SEQ ID NO: 4) (residues 62-65) of HCDR2 is selected from SGGT (SEQ ID NO: 5), NSNT (SEQ ID NO: 6), GGST (SEQ ID NO: 7) and SGNA (SEQ ID NO: 8) (IMGT nomenclature).

[0108] 3A. The antibody or antigen-binding fragment thereof according to paragraph 1A or 2A, wherein X1 of HCDR2 is P and X2X3X4X5 is SGGT (SEQ ID NO: 5) (IMGT nomenclature).

[0109] 4A. (a) the variable light chain (VL) is a kappa VL, and the amino acid sequence of LCDR1 is QSIX6X7R (SEQ ID NO: 70); the amino acid sequence of LCDR2 is EAS (SEQ ID NO: 71); and the amino acid sequence of LCDR3 is QQX8X9X 10 TPYT (SEQ ID NO:72), QQX8X9X 10 TPRVT (SEQ ID NO:73), QQX8X9X 10 FPRVS (SEQ ID NO: 74), or QQX8X9X 10 WPRT (SEQ ID NO: 75); wherein X6 is G or S; X7 is N or G; X8 is S or A; X9 is Y or N;10 is S or T; or (b) the VL is a lambda VL and the amino acid sequence of LCDR1 is SSDVGGYNX 11 (SEQ ID NO:76); the amino acid sequence of LCDR2 is EVT (SEQ ID NO:77); the amino acid sequence of LCDR3 is SSFKRGSTLVV (SEQ ID NO:14); 11 is Y or S; the sequence is defined according to the IMGT nomenclature. The antibody or antigen-binding fragment thereof according to any one of items 1A to 3A, comprising a VL domain comprising LCDR1, LCDR2 and LCDR3,

[0110] 5A. (a) CDRs of antibody G1AA / E12v2; (b) CDRs of antibody G1AA / G12v2; (c) CDRs of antibody G1AA / E05v2; (d) CDRs of antibody G1 / 887_04_E12; (e) CDRs of antibody G1 / 887_04_G12; (f) CDRs of antibody G1 / 894_08_E05; (g) CDRs of antibody G1 / 894_08_A05; (h) the CDRs of the antibody G1AA / lambdav3; or (i) CDRs of antibody G1 / 280_02_G02_NS; (j) CDRs of antibody G1 / 280_02_G02; The antibody or antigen-binding fragment thereof of any one of paragraphs 1A to 4A, comprising an antigen-binding site comprising:

[0111] With monoclonal and other antibodies, recombinant DNA technology techniques can be used to produce other antibodies or chimeric molecules that generally retain the specificity of the original antibody. Such techniques may involve introducing CDRs into different immunoglobulin frameworks or grafting variable regions into different immunoglobulin constant regions. The introduction of CDRs from one immunoglobulin into another is described, for example, in EP-A-184187, GB-A-2188638A, or EP-A-239400. Alternatively, the hybridoma or other cells that produce the antibody molecules may be subject to genetic mutations or other changes that may or may not alter the binding specificity of the antibody produced.

[0112] Since antibodies can be modified in many ways, the term "antibody" should be interpreted to cover antibody fragments, derivatives, functional equivalents, and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or wholly or partially synthetic. Thus, chimeric molecules comprising an immunoglobulin binding domain or equivalent fused to another polypeptide are included. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.

[0113] An example of an antibody fragment containing both CDR sequences and a CH3 domain is a minibody, which contains an scFv linked to a CH3 domain (Hu et al., 1996).

[0114] The antibodies or antigen-binding fragments of the invention bind to PD-L1, particularly human PD-L1. Binding in this context may refer to specific binding. The term "specific" may refer to the situation where an antibody molecule does not show significant binding to molecules other than its specific binding partner (here, PD-L1). The term "specific" may also be applied when the antibody molecule is specific for a particular epitope carried by some antigens, such as an epitope on PD-L1, in which case the antibody molecule can bind to a variety of antigens carrying the epitope.

[0115] Amino acids may be referred to by their one-letter or three-letter codes or full names. The one-letter and three-letter codes and full names for each of the 20 common amino acids are given below:

[0116] [Table 1-1]

[0117] In a preferred embodiment, the PD-L1 antibody of the invention comprises the HCDR3 sequence of E12v2 (SEQ ID NO:3); preferably the antibody further comprises the HCDR2 sequence of E12v2 (SEQ ID NO:18); preferably the PD-L1 antibody of the invention further comprises the HCDR1 sequence of E12v2 (SEQ ID NO:1). In a preferred embodiment, the HCDR2 sequence is the HCDR2 sequence of E12v2 (SEQ ID NO:18), and the amino acid at position 28 in VH (Kabat) is proline. In a particularly preferred embodiment, the PD-L1 antibody of the invention comprises the HCDR3 sequence of SEQ ID NO:3, the HCDR2 sequence of SEQ ID NO:18, and the HCDR1 sequence of SEQ ID NO:1, and the amino acid at position 28 in VH (Kabat) is proline. In a more particularly preferred embodiment, the PD-L1 antibody of the invention comprises the HCDR3 sequence of SEQ ID NO:3, the HCDR2 sequence of SEQ ID NO:18, and the HCDR1 sequence of SEQ ID NO:1, and the amino acid at position 28 in VH (Kabat) is proline.

[0118] An antibody of the invention may include one or more, for example 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, additional amino acid modifications in the VH and / or VL sequence, provided that the functional properties of the antibody are retained.

[0119] The modification may be an amino acid substitution, deletion or insertion. Preferably, the modification is a substitution.

[0120] In preferred embodiments where one or more amino acids are replaced with another amino acid, the substitutions may be conservative substitutions, for example according to the following chart: In some embodiments, amino acids in the same category in the middle column are replaced with each other, i.e., a non-polar amino acid is replaced with another non-polar amino acid, for example. In some embodiments, amino acids in the same row in the right-most column are replaced with each other.

[0121] [Table 1-2]

[0122] In some embodiments, substitutions may be functionally conservative, i.e., in some embodiments, the substitution may not affect (or may not substantially affect) one or more functional properties (e.g., binding affinity) of an antibody molecule that contains the substitution, compared to a comparable unsubstituted antibody molecule.

[0123] In a preferred embodiment, the PD-L1 antibodies of the invention may comprise a VH and / or VL domain sequence with one or more amino acid sequence alterations (additions, deletions, substitutions and / or insertions of amino acid residues), preferably no more than 20 alterations, no more than 15 alterations, no more than 10 alterations, no more than 5 alterations, no more than 4 alterations, no more than 3 alterations, no more than 2 alterations, or 1 alteration, compared to the VH and / or VL sequences of the invention described herein.

[0124] In a preferred embodiment, an antibody of the invention comprises the HCDR3 domain of E12v2 as set forth in SEQ ID NO:3.

[0125] In another preferred embodiment, an antibody of the invention comprises a VH domain of E12v2 set forth in SEQ ID NO:27, or a VH domain having an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO:27.

[0126] In a preferred embodiment, an antibody of the invention comprises a VH domain comprising an HCDR3 as set forth in SEQ ID NO:3, wherein the VH domain has an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO:27.

[0127] In a preferred embodiment, an antibody of the invention comprises a VH domain comprising an HCDR3 of E12v2 as set forth in SEQ ID NO: 3, and an HCDR2 selected from those set forth in SEQ ID NO: 18, 23 or 24, wherein the VH domain has an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 27.

[0128] In a preferred embodiment, an antibody of the invention comprises a VH domain comprising an HCDR3 of E12v2 as set forth in SEQ ID NO: 3, an HCDR2 domain selected from those set forth in SEQ ID NO: 18, 23 or 24, and a proline at position 28, wherein the VH domain has an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 27.

[0129] In a preferred embodiment, an antibody of the invention comprises a VL domain of E12v2 set forth in SEQ ID NO:28, or a VL domain comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO:28.

[0130] Sequence identity is generally defined with reference to the algorithm GAP (Wisconsin GCG Package, Accelerys Inc, San Diego USA). GAP uses the Needleman and Wunsch algorithm to align two complete sequences, maximizing the number of matches and minimizing the number of gaps. Generally, the default parameters are used, with a gap creation penalty equal to 12 and a gap extension penalty equal to 4. Although the use of GAP may be preferred, other algorithms may also be used, such as BLAST (using the method of Altschul et al. (1990) J. MoI. Biol. 215:405-410), FASTA (using the method of Pearson and Lipman (1988) PNAS USA 85:2444-2448), or the Smith-Waterman algorithm (Smith and Waterman (1981) J. MoI Biol. 147:195-197), or the TBLASTN program of Altschul et al. (1990), supra, generally using default parameters. In particular, the psi-Blast algorithm (Nucl. Acids Res. (1997) 25 3389-3402) may be used. Sequence identity may be defined using the Bioedit, ClustalW algorithm.

[0131] The antibody may comprise a CH2 domain. The CH2 domain is preferably located N-terminal to the CH3 domain, as in human IgG molecules. The CH2 domain of the antibody is preferably a human IgG1, IgG2, IgG3, or IgG4 CH2 domain, more preferably a human IgG1 CH2 domain. The sequences of human IgG domains are known in the art.

[0132] The antibody may comprise an immunoglobulin hinge region or a portion thereof at the N-terminus of the CH2 domain. The immunoglobulin hinge region allows the two CH2-CH3 domain sequences to associate to form a dimer. Preferably, the hinge region or a portion thereof is a human IgG1, IgG2, IgG3 or IgG4 hinge region or a portion thereof. More preferably, the hinge region or a portion thereof is an IgG1 hinge region or a portion thereof.

[0133] The sequence of the CH3 domain is not particularly limited. Preferably, the CH3 domain is a human immunoglobulin G domain, such as a human IgG1, IgG2, IgG3, or IgG4 CH3 domain, and most preferably, a human IgG1 CH3 domain.

[0134] The antibodies of the invention may comprise a human IgG1, IgG2, IgG3, or IgG4 constant region. The sequences of human IgG1, IgG2, IgG3, or IgG4 CH3 domains are known in the art.

[0135] The heavy chain of the antibody molecule may optionally include an additional lysine residue (K) at the C-terminus of the heavy chain CH3 domain sequence.

[0136] Immunoglobulins are known to have a modular architecture with individual domains, which can be combined in many different ways to create multispecific, e.g., bispecific, trispecific, or tetraspecific antibody formats. Exemplary multispecific antibody formats are described, for example, in Spiess et al., 2015 and Kontermann, 2012. The antibodies of the present invention can be used in such multispecific formats.

[0137] For example, the antibody of the present invention may be a heterodimeric antibody molecule, such as a heterodimeric complete immunoglobulin molecule, or a fragment thereof. In this case, the portion of the antibody will have a sequence as described herein. For example, if the antibody of the present invention is a bispecific heterodimeric antibody molecule, the antibody may comprise a heavy chain and a light chain as described herein paired with a heavy chain and a light chain comprising a VH domain and a VL domain, respectively, that bind an antigen other than PD-L1. Techniques for preparing heterodimeric antibodies are known in the art and include knob-into-hole (KIH) technology, which involves engineering the CH3 domain of an antibody molecule to create either a "knob" or a "hole" to promote chain heterodimerization. Alternatively, heterodimeric antibodies can be prepared by introducing charge pairs into the antibody molecule to avoid homodimerization of the CH3 domain due to electrostatic repulsion and direct heterodimerization due to electrostatic attraction. Examples of heterodimeric antibody formats include CrossMab, mAb-Fv, SEED-body, and KIH IgG.

[0138] Alternatively, a multispecific antibody molecule may comprise a complete immunoglobulin molecule or a fragment thereof and one or more additional antigen binding sites. The antigen binding sites may be, for example, Fv, scFv or single domain antibodies and may be fused to a complete immunoglobulin molecule or a fragment thereof. Examples of multispecific antibody molecules comprising additional antigen binding sites fused to a complete immunoglobulin molecule include DVD-IgG, DVI-IgG, scFv4-IgG, IgG-scFv and scFv-IgG molecules (Spiess et al., 2015; Figure 1). Examples of multispecific antibody molecules comprising additional antigen binding sites fused to an immunoglobulin fragment include, for example, BiTE molecules, diabodies and DART molecules (Spiess et al., 2015; Figure 1). Other suitable formats will be readily apparent to those skilled in the art.

[0139] In addition to the CDR-based PD-L1 binding site, for example in the VH of the antibody, the antibody may further comprise one or more additional antigen-binding sites to create a bi- or multispecific molecule. The antibody may comprise a CH3- or CH2-based antigen-binding site. CDR-based antigen-binding sites are found in naturally occurring immunoglobulin molecules and their structures are well known in the art. When the antibody or antigen-binding fragment thereof comprises a CDR-based antigen-binding site, the antibody or antigen-binding fragment thereof is preferably an antibody molecule. The bispecific or multispecific antibody molecule may comprise a CDR-based antigen-binding site of PD-L1 and a CH3- or CH2-based binding site of a second target. In a preferred embodiment, the antibody molecule is a human immunoglobulin G molecule, such as a human IgG1, IgG2, IgG3 or IgG4 molecule, more preferably a human IgG1 molecule.

[0140] Optionally, the antibody or antigen-binding fragment thereof of the invention may have a second antigen-binding site located in the constant domain of the antibody, preferably in CH3 or CH2.

[0141] Alternatively, or in addition, the antibody or antigen-binding fragment thereof of the invention may comprise an additional CDR-based antigen-binding site (e.g. formed by a VH and a VL) for a second or third target antigen. Thus, the antibody molecule or antigen-binding fragment thereof according to the invention may be a multispecific, preferably bispecific, molecule comprising a second antigen-binding site.

[0142] The second antigen-binding site, if present, may be a CH3- or CH2-based antigen-binding site or a CDR-based antigen-binding site and may bind to an antigen such that binding of said antigen is expected to be beneficial in the treatment of cancer.

[0143] The antibody molecule is called mAb. 2 (TM) bispecific antibodies. The mAbs referred to herein may be 2Bispecific antibodies are IgG immunoglobulins that contain a CDR-based antigen-binding site in each of their variable regions and at least one antigen-binding site in the constant domain of the antibody molecule.

[0144] In one embodiment, when the antibody or antigen-binding fragment thereof comprises a second antigen-binding site, e.g., a CH3-based, CH2-based, or CDR-based antigen-binding site, the second antigen-binding site may bind to a non-redundant and complementary inhibitory checkpoint molecule, such as CTLA-4, LAG-3, TIGIT, TIM-3, VISTA, CD73, CSF-1R, KIR, B7-H3, B7-H4, 2B4, NKG2A, CD47, SIRPa, BTLA, CCR4, CD200R, or TGF beta.

[0145] Inhibition of the PD-1 / PD-L1 axis and stimulation of costimulatory molecules represent complementary strategies to enhance immune responses in human patients. Reversal of T cell exhaustion through checkpoint blockade may allow these cells to be more potently activated and express full antitumor activity. Thus, in another embodiment, the antibody or antigen-binding fragment thereof of the present invention may comprise a second antigen-binding site, e.g., a CH3-based, CH2-based, or CDR-based antigen-binding site, which may bind to and be an agonist of a costimulatory molecule expressed by T cells, such as OX40, ICOS, CD40, HVEM, NKG2D, or TNFR2.

[0146] In further embodiments, the antibody or antigen-binding fragment thereof of the present invention may comprise a second antigen-binding site, e.g., a CH3-based, CH2-based, or CDR-based antigen-binding site, which may bind to a tumor-associated antigen (TAA). Such an antibody or antigen-binding fragment thereof is expected to induce tumor-specific T cell responses through local immune activation. Examples of TAAs are c-Met, B7-H3, B7-H4, EGFR, HER-2, EPCAM, CEACAM, FAP, VEGF, MSLN, GPC3, CD38, CD19, and CD20.

[0147] As detailed above, infectious diseases show many similarities with oncology. The role of PD-L1 in immune regulation may be exploited to maximize the immune response against pathogens. Immunomodulation in the treatment of infectious diseases is an emerging field of medicine, and early reviews suggest that PD-L1 blockade may improve the biological response to infection, specifically helping to counter T cell exhaustion, managing immune-mediated clearance, and generating long-term immunity (Wykes and Lewin, 2017).

[0148] In several infectious diseases, excessive proinflammatory responses and suboptimal antigen-specific T cell activity are responsible for severe tissue damage (Rao et al., 2017). Without wishing to be bound by theory, it is believed that the use of the antibodies or antigen-binding fragments thereof of the present invention comprising a second antigen-binding site may find use in the treatment of these diseases by localizing beneficial immunomodulatory activity to the pathogen environment.

[0149] Alternatively, the use of antibodies or antigen-binding fragments thereof of the invention that contain a second antigen-binding site that binds to an immune cell target for either agonistic or antagonistic activity can result in increased T cell specificity and activity.

[0150] Thus, in one embodiment, where the antibody or antigen-binding fragment thereof comprises a second antigen-binding site, the second antigen-binding site may bind to an immune cell target such as PD-1, PD-L2, CTLA-4, LAG-3, TIGIT, TIM3, OX40, CD40, ICOS, CD28, or CD80.

[0151] Alternatively, if the antibody or antigen-binding fragment thereof comprises a second antigen-binding site, the second antigen-binding site may bind to a pathogenic target, i.e., an antigen expressed by a human pathogen. The pathogen may be a virus, a bacterium, a fungus, or a parasite. Preferably, the pathogen is a virus, a bacterium, or a fungus. More preferably, the pathogen is a virus or a bacterium. Most preferably, the pathogen is a virus. Examples of viral antigens include proteins p24, gp120, and gp41 expressed by human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) expressed by hepatitis B virus (HBV), and hemagglutinin and neuraminidase expressed by influenza virus. Examples of bacterial antigens include Rv1733, Rv2389, and Rv2435n expressed by Mycobacterium tuberculosis.

[0152] In some embodiments, the second antigen-binding site of the antibody of the present invention may not bind to OX40. Additionally or alternatively, the second antigen-binding site of the antibody of the present invention may not bind to CD137. Additionally or alternatively, the second antigen-binding site of the antibody of the present invention may not bind to CD27. Additionally or alternatively, the second antigen-binding site of the antibody of the present invention may not bind to glucocorticoid-inducible TNFR-related protein (GITR). Additionally or alternatively, the second antigen-binding site of the antibody of the present invention may not bind to lymphocyte activation gene 3 (LAG-3). Additionally or alternatively, the second antigen-binding site of the antibody of the present invention may not bind to inducible T cell costimulator (ICOS).

[0153] The antibodies of the present invention may be conjugated to an immune system modulator, a cytotoxic molecule, a radioisotope or a detectable label. The immune system modulator may be a cytotoxic molecule such as a cytokine.

[0154] The antibody molecule may be conjugated to a biologically active molecule or a detectable label. In this case, the antibody molecule may be referred to as a conjugate. Such conjugates find use in the treatment and / or diagnosis of diseases as described herein.

[0155] For example, the bioactive molecule can be an immune system modulator, such as a cytokine, preferably a human cytokine. For example, the cytokine can be a cytokine that stimulates the activation and / or proliferation of T cells. Examples of cytokines for conjugation to antibody molecules include IL-2, IL-10, IL-12, IL-15, IL-21, GM-CSF, and IFN-gamma.

[0156] Alternatively, the bioactive molecule may be a ligand trap, such as a ligand trap for a cytokine, for example TGF-beta or IL-6.

[0157] Suitable detectable labels that can be conjugated to the antibody molecule are known in the art and include radioisotopes, such as iodine-125, iodine-131, yttrium-90, indium-111, technetium-99, etc.; fluorescent dyes, such as fluorescein, rhodamine, phycoerythrin, Texas Red, and cyanine dye derivatives (e.g., Cy7 and Alexa750); chromogenic dyes, such as diaminobenzidine; latex beads; enzyme labels, such as horseradish peroxidase; fluorophores or laser dyes with spectrally resolved absorption or emission characteristics; and chemical moieties, such as biotin, that can be detected via binding to a specific cognate detectable moiety (e.g., labeled avidin).

[0158] The antibody of the present invention can be conjugated to a biologically active molecule or a detectable label by any suitable covalent or non-covalent bond, such as a disulfide or peptide bond. When the biologically active molecule is a cytokine, the cytokine can be attached to the antibody molecule by a peptide linker. Suitable peptide linkers are known in the art and can be 5 to 25 amino acids, 5 to 20 amino acids, 5 to 15 amino acids, 10 to 25 amino acids, 10 to 20 amino acids, or 10 to 15 amino acids in length.

[0159] In some embodiments, the biologically active molecule may be conjugated to the antibody by a cleavable linker. The linker may allow the release of the biologically active molecule from the antibody at the therapeutic site. The linker may include an amide bond (e.g., a peptide linker), a disulfide bond, or a hydrazone. For example, a peptide linker may be cleaved by a site-specific protease, a disulfide bond may be cleaved by the reducing environment of the cytosol, and a hydrazone may be cleaved by acid-mediated hydrolysis.

[0160] The conjugate may be a fusion protein comprising an antibody of the invention and a biologically active molecule. In this case, the biologically active molecule may be conjugated to the antibody by a peptide linker or peptide bond. If the antibody is a multi-chain molecule, for example, if the antibody molecule is or comprises an Fcab, or is a mAb, 2 For example, the biologically active molecule may be conjugated to one or more chains of the antibody molecule. 2 It may be conjugated to one or both of the heavy chains of the molecule. Fusion proteins have the advantage of being easy to produce and purify, facilitating the production of clinical grade material.

[0161] The present invention also provides a nucleic acid or set of nucleic acids encoding the antibody or antigen-binding fragment of the present invention, and a vector comprising such a nucleic acid or set of nucleic acids.

[0162] When a nucleic acid encodes the VH and VL domains, or the heavy and light chains, of an antibody molecule of the invention, the two domains or chains may be encoded on two separate nucleic acid molecules.

[0163] The isolated nucleic acid molecule may be used to express the antibody molecule of the present invention. The nucleic acid is generally provided in the form of a recombinant vector for expression. Thus, another aspect of the present invention provides a vector comprising the nucleic acid as described above. A suitable vector can be selected or constructed containing appropriate regulatory sequences, including promoter sequences, transcription termination fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as needed. Preferably, the vector contains appropriate regulatory sequences to drive the expression of the nucleic acid in a host cell. The vector may be a plasmid, viral, e.g., phage, or phagemid, as needed.

[0164] The nucleic acid molecules or vectors described herein may be introduced into a host cell. Techniques for introducing nucleic acids or vectors into a host cell are well established in the art and any suitable technique may be used. A variety of host cells suitable for the production of recombinant antibody molecules are known in the art and include bacterial, yeast, insect or mammalian host cells. Preferred host cells are mammalian cells such as CHO, NS0 or HEK cells, e.g. HEK293 cells.

[0165] Recombinant host cells comprising the nucleic acid or vector of the invention are also provided. Such recombinant host cells can be used to produce the antibodies of the invention. Accordingly, a method of producing the antibodies of the invention is also provided, which comprises culturing the recombinant host cells under conditions suitable for the production of the antibodies. The method may further comprise the step of isolating and / or purifying the antibody molecules.

[0166] Thus, the present invention provides a method for producing an antibody molecule of the present invention, comprising expressing a nucleic acid encoding the antibody molecule in a host cell and, optionally, isolating and / or purifying the antibody molecule so produced. Methods for culturing host cells are well known in the art. Techniques for purifying recombinant antibody molecules are well known in the art and include, for example, HPLC, FPLC or affinity chromatography (e.g., using Protein A or Protein L). In some embodiments, purification may be performed using an affinity tag on the antibody molecule. The method may also include formulating the antibody molecule, optionally with a pharma- ceutical composition, together with a pharma- ceutical acceptable excipient or other substances as described below.

[0167] The antibodies of the present invention are expected to find use in therapeutic applications, particularly in humans, such as the treatment of cancer and the treatment of infectious diseases. Accordingly, compositions, such as pharmaceutical compositions, comprising an antibody molecule according to the present invention, and excipients, such as pharma- ceutically acceptable excipients, are also provided.

[0168] The present invention further provides an antibody molecule of the present invention for use in a method of treatment. A method of treating a patient is also provided, which comprises administering to the patient a therapeutically effective amount of an antibody molecule according to the present invention. Furthermore, there is provided the use of an antibody molecule of the present invention for use in the manufacture of a medicament. As referred to herein, the patient is preferably a human patient.

[0169] The present invention also provides the antibody molecule of the present invention for use in a method of treating cancer in a patient. A method of treating cancer in a patient is also provided, comprising administering to the patient a therapeutically effective amount of an antibody molecule according to the present invention. Further, there is provided the use of an antibody molecule according to the present invention for use in the manufacture of a medicament for treating cancer in a patient. The treatment may further comprise administering to the patient a second anti-cancer agent and / or treatment, such as an anti-tumor vaccine and / or a chemotherapeutic agent. The second anti-cancer agent and / or treatment may be administered to the patient simultaneously, separately or sequentially with the antibody molecule of the present invention.

[0170] In another aspect, the present invention provides a method for producing a pharmaceutical composition comprising: a) treating cancer; b) delaying the progression of cancer; c) prolonging survival of a patient suffering from cancer; or d) stimulating a cell-mediated immune response. The present invention relates to an antibody that binds to PD-L1 for use in

[0171] The present invention also provides an antibody of the present invention for use in a method of treating an infectious disease in a patient. A method of treating an infectious disease in a patient is also provided, comprising administering to the patient a therapeutically effective amount of an antibody according to the present invention. Further, a use of an antibody according to the present invention for use in the manufacture of a medicament for treating an infectious disease in a patient is provided. The treatment may further comprise administering to the patient a second agent and / or therapy for the treatment of the infectious disease. The second agent and / or therapy may be administered to the patient simultaneously, separately or sequentially with the antibody or antigen-binding fragment thereof or antibody molecule of the present invention.

[0172] Thus, the antibody molecules described herein may be useful in therapeutic applications, particularly in the treatment of cancer. Furthermore, it is expected that the antibody molecules will be useful in the treatment of infectious diseases, such as persistent infections. The antibody molecules described herein may be used in methods of treatment of the human or animal body. (i) an antibody molecule as described herein for use as a medicament; (ii) an antibody molecule as described herein for use in a method for the treatment of a disease or disorder; (iii) use of an antibody molecule described herein in the manufacture of a medicament for use in the treatment of a disease or disorder; and (iv) A method for treating a disease or disorder in an individual, comprising administering to the individual a therapeutically effective amount of an antibody molecule described herein. to provide.

[0173] The individual may be a patient, preferably a human patient.

[0174] Treatment can be any treatment or therapy that achieves some desired therapeutic effect, such as, for example, inhibiting or slowing the progression of a condition, including slowing the rate of progression, halting the rate of progression, improving the condition, curing or ameliorating (partially or totally) the condition, preventing, ameliorating, delaying, alleviating, or arresting one or more symptoms and / or signs of the condition, or prolonging the survival of an individual or patient beyond that expected in the absence of treatment.

[0175] Treatment as a preventative measure (i.e., prophylaxis) is also included. For example, an individual susceptible to or at risk of developing or recurring a disease, such as cancer, can be treated as described herein. Such treatment can prevent or delay the development or recurrence of the disease in the individual.

[0176] The treatment method as described may include administering at least one additional treatment to an individual in addition to the antibody molecule. Thus, the antibody molecule described herein may be administered to an individual alone or in combination with one or more other treatments. When the antibody molecule is administered to an individual in combination with another treatment, the additional treatment may be administered to the individual simultaneously, sequentially, or separately from the administration of the antibody molecule. When the additional treatment is administered simultaneously with the antibody molecule, the antibody molecule and the additional treatment may be administered to the individual as a combined preparation. For example, the additional treatment may be a known treatment or therapeutic agent for the disease being treated.

[0177] Although antibody molecules can be administered alone, antibody molecules are usually administered in the form of pharmaceutical compositions that may contain at least one component in addition to the antibody molecule.Accordingly, another aspect of the present invention provides pharmaceutical compositions that contain the antibody molecules described herein.Methods are also provided that include formulating antibody molecules into pharmaceutical compositions.

[0178] In addition to the antibody molecule, the pharmaceutical composition may include pharma- ceutically acceptable excipients, carriers, buffers, stabilizers, or other materials known to those skilled in the art. The term "pharmacologically acceptable" as used herein refers to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of a subject (e.g., a human) without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation. The precise nature of the carrier or other material will depend on the route of administration, which may be by infusion, injection, or other suitable route, as discussed below.

[0179] For parenteral, e.g., subcutaneous or intravenous administration (e.g., by injection), pharmaceutical compositions containing the antibody molecule may be in the form of a parenterally acceptable aqueous solution that is pyrogen-free and has appropriate pH, isotonicity and stability. Those skilled in the relevant art are well able to prepare suitable solutions using, for example, isotonic vehicles such as sodium chloride injection, Ringer's injection, lactated Ringer's injection, etc. Buffers such as phosphate, citric acid and other organic acids; antioxidants such as ascorbic acid and methionine; preservatives (octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3'-pentanol; and m-cresol); low molecular weight polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; glycosyltransferases such as glycerol, ... Preservatives, stabilizers, buffers, antioxidants and / or other additives may be used as needed, including amino acids such as lysine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG).

[0180] In some embodiments, the antibody molecule may be provided in lyophilized form for reconstitution prior to administration, for example, lyophilized antibody molecules may be reconstituted with sterile water or saline prior to administration to an individual.

[0181] The administration may be a "therapeutically effective amount", which is sufficient to show benefit to the individual. The amount actually administered, as well as the rate and time course of administration, will depend on the nature and severity of the subject being treated, the particular individual being treated, the individual's clinical condition, the cause of the disorder, the site of delivery of the composition, the type of antibody molecule, the method of administration, the schedule of administration, and other factors known to the physician. Prescription of treatment, such as determining dosage, is within the responsibility of general practitioners and other physicians and may depend on the severity of the condition and / or the progression of the disease being treated. Appropriate dosages of antibody molecules are well known in the art (Ledermann et al., 1991; Bagshawe et al., 1991). Specific dosages as set forth herein or in the Physician's Desk Reference (2003) appropriate for the antibody molecule being administered may be used. Therapeutically effective amounts or appropriate dosages of antibody molecules can be determined by comparing in vitro and in vivo activity in animal models. Methods for extrapolating effective dosages in mice and other test animals to humans are known. The exact dose will depend on a number of factors, including the size and location of the area to be treated, and the precise nature of the antibody molecule.

[0182] Typical antibody doses range from 100 μg to 1 g for systemic administration and 1 μg to 1 mg for local administration. An initial higher loading dose may be administered, followed by one or more lower doses. This is the dose for a single treatment of an adult individual and can be adjusted proportionally for children and infants, and for other antibody formats proportional to molecular weight.

[0183] Treatments may be repeated daily, twice weekly, weekly, or monthly, at the physician's discretion. An individual's treatment schedule may depend on the pharmacokinetic and pharmacodynamic properties of the antibody composition, the route of administration, and the nature of the condition being treated.

[0184] Treatment can be periodic, with the period between administrations being about 2 weeks or more, e.g., about 3 weeks or more, about 4 weeks or more, about monthly or more, about 5 weeks or more, or about 6 weeks or more. For example, treatment can be every 2 to 4 weeks, or every 4 to 8 weeks. Suitable formulations and routes of administration are described above.

[0185] In a preferred embodiment, the antibody molecules described herein may be for use in methods of treating cancer.

[0186] Cancer can be characterized by the abnormal proliferation of malignant cancer cells.When referring to a particular type of cancer, such as breast cancer, this refers to the abnormal proliferation of malignant cells in related tissues, such as breast tissue.A secondary cancer that is located in the breast but is the result of the abnormal proliferation of malignant cells in another tissue, such as ovarian tissue, is not breast cancer as referred to herein, but ovarian cancer.

[0187] The cancer may be a primary cancer or a secondary cancer. Thus, the antibody molecules described herein may be for use in a method of treating cancer in an individual, where the cancer is a primary tumor and / or a tumor metastasis.

[0188] Cancer tumors to be treated using the antibody molecules described herein may contain cells that express PD-L1, for example on their cell surface. In one embodiment, the tumor may be one that has been determined to contain cells that express PD-L1. Methods for determining expression of antigens on the cell surface are known in the art and include, for example, flow cytometry.

[0189] For example, cancers that may be treated using the antibody molecules described herein include leukemias, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL); lymphomas, such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, and multiple myeloma; as well as sarcomas (e.g., soft tissue sarcoma), skin cancer (e.g., Merkel cell carcinoma), melanoma, bladder cancer (e.g., urothelial carcinoma), brain cancer (glioblastoma multiforme), breast cancer, uterine / endometrial cancer, ovarian cancer (e.g., ovarian serous cystoma), and tumors. and / or ovarian cancer, such as ovarian cancer, ...

[0190] In a preferred embodiment, the cancer to be treated using the antibody molecules described herein is a solid cancer. More preferably, the cancer to be treated using the antibody molecules described herein is a solid cancer selected from the group consisting of sarcoma, melanoma, bladder cancer, brain cancer, breast cancer, ovarian cancer, uterine / endometrial cancer, prostate cancer, lung cancer, colorectal cancer, cervical cancer, liver cancer, head and neck cancer, pancreatic cancer, renal cancer, and gastric cancer.

[0191] In cancer, treatment may include inhibiting cancer growth, including complete cancer remission, and / or inhibiting cancer metastasis, and inhibiting cancer recurrence. Cancer growth generally refers to any of a number of indicators that indicate a change in cancer to a more developed form. Thus, indicators for measuring inhibition of cancer growth include reduced survival of cancer cells, reduction in tumor volume or morphology (e.g., as determined using computed tomography (CT), ultrasound, or other imaging methods), slowing tumor growth, disruption of tumor vasculature, improved performance of delayed-type hypersensitivity skin test, increased activity of anti-cancer immune cells or other anti-cancer immune responses, and reduced levels of tumor-specific antigens. Activating or enhancing an individual's immune response to a cancerous tumor may improve the individual's ability to resist cancer growth, particularly the growth of cancer already present in the subject, and / or reduce the individual's propensity for cancer growth.

[0192] In the treatment of cancer, the antibody molecules described herein may be administered to an individual in combination with another anti-cancer therapy or treatment, such as an anti-cancer therapy or treatment shown to be or expected to be suitable for the treatment of the cancer in question. For example, the antibody molecules may be administered to an individual in combination with an agent for chemotherapy, radiation therapy, immunotherapy, anti-tumor vaccines, oncolytic viruses, adoptive cell transfer (ACT) therapy (such as adoptive NK cell therapy) or treatment with chimeric antigen receptors (CARs), autologous tumor infiltrating lymphocytes (TILs), or gamma / delta T cells, or hormonal therapy.

[0193] Without wishing to be bound by theory, it is believed that the antibody molecules described herein may act as adjuvants in anti-cancer treatments. Specifically, it is believed that administration of the antibody molecules to an individual in combination with, for example, chemotherapy and / or radiation therapy, or in combination with an anti-tumor vaccine, induces a greater immune response against cancer than is achieved by chemotherapy and / or radiation therapy, or an anti-tumor vaccine alone.

[0194] The one or more chemotherapeutic agents for administration in combination with the antibodies of the invention as described herein may be selected from the group consisting of taxanes, cytotoxic antibiotics, tyrosine kinase inhibitors, PARP inhibitors, B-Raf enzyme inhibitors, MEK inhibitors, c-MET inhibitors, VEGFR inhibitors, PDGFR inhibitors, alkylating agents, platinum analogs, nucleoside analogs, antifolates, thalidomide derivatives, antineoplastic chemotherapeutic agents, etc. Taxanes include docetaxel, paclitaxel, and nab-paclitaxel; cytotoxic antibiotics include actinomycin, bleomycin, and anthracyclines such as doxorubicin, mitoxantrone, and valrubicin; tyrosine kinase inhibitors include erlotinib, gefitinib, axitinib, PLX3397, imatinib, cobemitinib, and trametinib; PARP inhibitors include pilaparib. B-Raf enzyme inhibitors include vemurafenib and dabrafenib; alkylating agents include dacarbazine, cyclophosphamide and temozolomide; platinum analogs include carboplatin, cisplatin and oxaliplatin; nucleoside analogs include azacitidine, capecitabine, fludarabine, fluorouracil and gemcitabine; antifolates include methotrexate and pemetrexed. Other chemotherapeutic agents suitable for use in the present invention include defactinib, entinostat, eribulin, irinotecan, and vinblastine.

[0195] Preferred therapeutic agents for administration with the antibody molecules described herein are doxorubicin, mitoxantrone, cyclophosphamide, cisplatin, and oxaliplatin.

[0196] Radiation therapy for administration in combination with an antibody molecule as described herein can be external beam radiation therapy or brachytherapy.

[0197] The immunotherapeutic agent for administration in combination with the antibody molecule as described herein may be a therapeutic antibody molecule, a nucleic acid, a cytokine, or a cytokine-based therapeutic agent. For example, the therapeutic antibody molecule may bind to an immunomodulatory molecule, such as an inhibitory checkpoint molecule or an immune co-stimulatory molecule, a receptor of the innate immune system, or a tumor antigen, such as a cell surface tumor antigen or a soluble tumor antigen. Examples of immunomodulatory molecules to which the therapeutic antibody molecule may bind include CTLA-4, LAG-3, TIGIT, TIM-3, VISTA, PD-1, CD47, CD73, CSF-1R, KIR, OX40, CD40, HVEM, IL-10, and CSF-1. Examples of receptors of the innate immune system to which the therapeutic antibody molecule may bind include TLR1, TLR2, TLR4, TLR5, TLR7, TLR9, RIG-I-like receptors (e.g., RIG-I and MDA-5), and STING. Examples of tumor antigens to which therapeutic antibody molecules may bind include HER2, EGFR, CD20 and TGF-beta.

[0198] The nucleic acid for administration in combination with an antibody molecule as described herein may be an siRNA.

[0199] The cytokine or cytokine-based therapy may be selected from the group consisting of IL-2, a prodrug of conjugated IL-2, GM-CSF, IL-7, IL-12, IL-9, IL-15, IL-18, IL-21, and type I interferon.

[0200] Antitumor vaccines for the treatment of cancer have been implemented in the clinic and have been extensively discussed in the scientific literature (e.g., Rosenberg S. Development of Cancer Vaccines. ASCO Educational Book Spring:60-62 (2000)). This primarily involves strategies to stimulate the immune system to respond to various cell markers expressed by autologous or allogeneic cancer cells by using these cells as a vaccination method, both with and without granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF induces a strong response in antigen presentation and works particularly well when used in the strategy.

[0201] The chemotherapeutic agent, radiotherapy, immunotherapy, antitumor vaccine, oncolytic virus, ACT therapy, or hormonal therapy agent is preferably a chemotherapeutic agent, radiotherapy, immunotherapy, antitumor vaccine, oncolytic virus, ACT therapy, or hormonal therapy agent for the cancer in question, i.e., a chemotherapeutic agent, radiotherapy, immunotherapy, antitumor vaccine, oncolytic virus, ACT therapy, or hormonal therapy agent that has been shown to be effective in treating the cancer in question. The selection of a suitable chemotherapeutic agent, radiotherapy, immunotherapy, antitumor vaccine, oncolytic virus, ACT therapy, or hormonal therapy agent that has been shown to be effective for the cancer in question is well within the capabilities of a person skilled in the art.

[0202] In some embodiments for potential therapeutic use, antibodies that do not activate effector functions are preferred.

[0203] Although IgG4 has been used, this subclass can undergo Fab arm exchange and exchange heavy chains between IgG4s in vivo. Due to the lack of effector functions, IgG4 antibodies represent the preferred IgG subclass for blocking receptors without depleting cells. IgG4 molecules can exchange half molecules in a dynamic process called Fab arm exchange. This phenomenon can occur between therapeutic antibodies and endogenous IgG4. The S228P mutation has been shown to prevent this recombination process, allowing the design of less unpredictable therapeutic IgG4 antibodies.

[0204] The CH2 domain is known to bind to Fcγ receptors and complement. Binding of the CH2 domain to Fcγ receptors is required for antibody-dependent cell-mediated cytotoxicity (ADCC), while binding to complement is required for complement-dependent cytotoxicity (CDC). The CH2 domain of the antibody molecule preferably contains one or more mutations that reduce or inhibit binding of the CH2 domain to one or more FcγRI, FcγRIIa, FcγRIIb, FcγRIII, and / or complement. The inventors hypothesize that by reducing or inhibiting binding to Fcγ receptors, ADCC mediated by the antibody molecule is reduced or eliminated. Similarly, reducing or inhibiting binding to complement is expected to reduce or eliminate CDC mediated by the antibody molecule. Without wishing to be bound by theory, this is expected to reduce or avoid liver inflammation when the antibody molecule is administered to a patient. Furthermore, reducing or inhibiting binding to Fcγ receptors is expected to be useful when the antibody molecule comprises a second antigen-binding site for an immune cell antigen as described herein, where killing of immune cells bound by the antibody molecule via ADCC and / or CDC should be avoided. Mutations that reduce or inhibit binding of the CH2 domain to one or more Fcγ receptors and / or complement are known in the art (Wang et al., 2018). These mutations include the "LALA mutations" described in Bruhns et al., 2009 and Hezareh et al., 2001, which involve replacing the leucine residues at IMGT positions 1.3 and 1.2 of the CH2 domain with alanines (L1.3A and L1.2A). Alternatively, generation of α-glycosylated antibodies through mutation of a conserved N-linked glycosylation site by mutating the asparagine (N) at position IMGT84.4 in the CH2 domain to alanine, glycine, or glutamine (N84.4A, N84.4G, or N84.4Q) is also known to reduce IgG1 effector function ( Wang et al., 2018 ).As a further alternative, complement activation (C1q binding) and ADCC are known to be reduced by mutating the proline at position IMGT114 in the CH2 domain to alanine or glycine (P114A or P114G) (Idusogie et al., 2000; Klein et al., 2016). These mutations can also be combined to generate antibody molecules with even reduced or no ADCC or CDC activity.

[0205] Thus, the antibody molecule may comprise a CH2 domain, wherein the CH2 domain preferably comprises (i) alanine residues at positions 1.3 and 1.2; and / or (ii) alanine or glycine at position 114; and / or (iii) alanine, glutamine or glycine at position 84.4; where the numbering of the amino acid residues is according to the IMGT numbering scheme.

[0206] In a preferred embodiment, the antibody molecule comprises a CH2 domain, wherein the CH2 domain comprises: (i) an alanine residue at position 1.3; and (ii) an alanine residue at position 1.2; where the numbering of the amino acid residues is according to the IMGT numbering scheme.

[0207] In an alternative preferred embodiment, the antibody molecule comprises a CH2 domain, wherein the CH2 domain comprises: (i) an alanine residue at position 1.3; (ii) an alanine residue at position 1.2; and (iii) alanine at position 114; where the numbering of the amino acid residues is according to the IMGT numbering scheme.

[0208] IgG naturally persists for a long time in serum due to FcRn-mediated recycling, with a typical half-life of approximately 21 days. To extend the half-life, the pH-dependent interaction of the Fc domain with FcRn has been engineered to increase affinity at pH 6.0 while maintaining minimal binding at pH 7.4. The mutation T250Q / M428L increased IgG half-life in rhesus monkeys by approximately 2-fold. The M252Y / S254T / T256E mutant (called YTE) increased IgG half-life in cynomolgus monkeys by approximately 4-fold. A longer half-life is desirable in some situations to reduce the frequency of administration while maintaining or improving the efficacy of the administered antibody. The antibodies of the invention may be provided as half-life extended mutants engineered to extend their in vivo serum half-life following administration, and thus the antibodies of the invention may be provided as T250Q / M428L or M252Y / S254T / T256E mutants.

[0209] The antibody molecules of the present invention may be useful for the detection of PD-L1, and in particular for the detection of cells which contain PD-L1 on their cell surface, i.e. cells which express PD-L1 bound to their cell surface. + T cells, CD4 + The cells may be immune cells such as T cells, Treg cells, B cells, NK cells, NKT cells, dendritic cells, or TILs, but are preferably CD8 + T cells or TILs.

[0210] Thus, the invention relates to the use of an antibody molecule to detect the presence of PD-L1 in a sample, preferably the presence of cells which contain PD-L1 on their cell surface. The antibody molecule may be conjugated to a detectable label, as described elsewhere herein.

[0211] Also provided is an in vitro method of detecting PD-L1, which comprises incubating an antibody molecule with a sample of interest and detecting binding of the antibody molecule to the sample, where binding of the antibody to the sample indicates the presence of PD-L1. Binding of the antibody molecule to the sample can be detected using, for example, ELISA.

[0212] In a preferred embodiment, the invention relates to an in vitro method for detecting cells which contain PD-L1 on their cell surface, the method comprising incubating an antibody molecule with a cell sample of interest and determining binding of the antibody molecule to cells present in the sample, where binding of the antibody to cells present in the sample indicates the presence of cells which contain PD-L1 on their cell surface. Methods for detecting binding of antibody molecules to cells are known in the art and include ELISA and flow cytometry.

[0213] The cell sample of interest may be a tumor sample obtained from an individual.

[0214] The antibody molecule of the present invention may therefore be useful for the detection or diagnosis of a disease or disorder, in particular the detection or diagnosis of cancer, which may be a cancer that can be treated with the antibody molecule of the present invention as described herein.

[0215] Accordingly, a related aspect of the invention is (i) an antibody molecule as described herein for use as a diagnostic; (ii) an antibody molecule as described herein for use in a method for detecting or diagnosing a disease or disorder, such as cancer; (iii) the use of an antibody molecule described herein in the manufacture of a diagnostic agent for use in the detection or diagnosis of a disease or disorder; (iv) a method for detecting or diagnosing a disease or disorder in an individual; and (v) A kit for use in a method for detecting or diagnosing a disease or disorder in an individual, comprising an antibody molecule as described herein. to provide.

[0216] Further aspects and embodiments of the present invention will be apparent to those of skill in the art given this disclosure, including the experimental exemplification that follows.

[0217] All documents mentioned herein are incorporated herein by reference in their entirety.

[0218] As used herein, "and / or" should be interpreted as a specific disclosure of each of two particular features or components, with or without the other. For example, "A and / or B" should be interpreted as a specific disclosure of each of (i) A, (ii) B, and (iii) A and B, just as if each were individually set forth herein.

[0219] Unless the context dictates otherwise, the above feature descriptions and definitions are not limited to any particular aspect or embodiment of the invention, but apply equally to all aspects and embodiments described.

[0220] Certain aspects and embodiments of the present invention will now be described, by way of example, with reference to the figures provided herein. [Brief description of the drawings]

[0221] Drawing List [Figure 1] Mixed leukocyte reaction assay. The functional activity of the anti-PD-L1 kappa clones, G1 / 894_8_E05, G1 / 887_4_E12, and G1 / 887_4_G12, was tested in a mixed leukocyte reaction assay. All anti-PD-L1 mAbs showed potent activity with EC50 values ​​less than 0.030 nM. No activity was observed for the negative control G1AA / 4420. [Diagram 2] DO11.10 Mouse T Cell Activation Assay. The functional activity of anti-PD-L1 kappa clones, G1 / 894_8_E05, G1 / 887_4_E12, and G1 / 887_4_G12 against mouse PD-L1 was tested in a T cell assay using LK35.2 overexpressing mouse PD-L1 and DO11.10 T cells. All anti-PD-L1 mAbs showed potent activity with low nanomolar EC50 values. No activity was observed for the negative control G1AA / 4420. [Diagram 3] Pharmacokinetics of anti-PD-L1 mAb in non-tumor-bearing mice. [Figure 4]Mixed leukocyte reaction assay. The functional activity of the anti-PD-L1 kappa clones, G1AA / E05v2, G1AA / E12v2 and G1AA / G12v2, was tested in a mixed leukocyte reaction assay. All anti-PD-L1 mAbs showed potent activity with EC50 values ​​less than 0.055 nM. No activity was observed for the negative control G1AA / 4420. EXAMPLES

[0222] Working Example The goal of these experiments was to generate anti-human PD-L1 mAbs that are cross-reactive with mouse and / or cynomolgus PD-L1 and are potent inhibitors (blockers) of PD-1 / PD-L1 activity.

[0223] Example 1: Isolation of naive anti-PD-L1 binding mAb: 280_02_G02 1.1 Antigens: CD4 and Fc-tagged human and mouse PD-L1 Human and mouse PD-L1 antigen-containing fusion proteins have been generated for use in antibody selection and screening. Antigens were expressed with either a monomeric C-terminal rat CD4, domains 3 and 4 (rCd4) tag (Brown and Barclay, 1994), or a dimeric human IgG1 Fc domain (hPD-L1-rCD4-His (SEQ ID NO: 79), hPD-L1-Fc-His (SEQ ID NO: 80), mPD-L1-rCD4-His (SEQ ID NO: 81) and mPD-L1-Fc-His (SEQ ID NO: 82). Production of antigens in two different formats allowed removal of tag binders during sequential antibody phage display panning. Expression plasmids encoding the antigens were transfected into HEK293 cells as described in Chapple et al., 2006. Supernatants were harvested 5 days post-transfection and secreted antigens were purified by Ni-NTA sepharose affinity chromatography (Schofield et al., 2007). Biotinylated antigens were purified using EZ-link Biotin was prepared using Sulfo-NHS-Biotin reagent (Thermo Fisher Scientific, product code 21326) according to the manufacturer's recommendations. The biotinylated reaction products were gel filtered and the monomer fraction was collected. The monomer fraction was used for all solution-phase phage display selections. The average number of biotins per molecule, determined using a fluorescent biotin quantification kit (Thermo Fisher Scientific, product code 46610), ranged from 1 to 3 biotins per PD-L1 monomer.

[0224] 1.2 Selection 1.2.1 Library Design The "IONTAS 1" human antibody phage display library (IONTAS Ltd.) was used to select anti-PD-L1 clones. Antibody genes used for the construction of the IONTAS 1 library were derived from human lymphocytes (42 buffy coat donations) and one tonsil tissue sample. Both buffy coat and tonsil tissue were obtained under the approval of the Local Research Ethical Committee.

[0225] 1.2.2 Naive solid-phase selection Three rounds of solid-phase selection were performed with the IONTAS1 antibody phage display library using antigen directly coated onto polystyrene Nunc tubes as described in Schofield et al., 2007. The first, second, and third selection rounds used human PD-L1-Fc-His (SEQ ID NO: 80), mouse PD-L1-rCD4-His (SEQ ID NO: 81), and human PD-L1-Fc-His (SEQ ID NO: 80), respectively. In the first round, Nunc Maxisorp Immunotubes (Thermo Scientific, 444202) were coated overnight with 10μg / ml human PD-L1-Fc-His for direct selection. The next day, the tubes were rinsed twice with PBS, then blocked by filling to the top with PBS2% Marvel / PBS (MPBS) and incubated for 1 hour, after which the tubes were washed three times with PBS. In addition, the IONTAS 1 antibody phage display library (500 μl) was blocked with 4% MPBS (500 μl) for 1 hour. 2% MPBS (179.25 μl), Fc-His (10.75 μl, 2.8 mg / ml) and the blocked IONTAS 1 antibody phage display library (110 μl, 2 × 10 12Colony forming units, 2% MPBS) was added. Fc-His was added to the selection to remove anti-Fc binders that bound to the solid phase immobilized Fc-tagged antigen. The antibody phage display library was allowed to bind to the directly immobilized antigen for 1.5 hours at room temperature. After this, the immunotubes were washed six times with PBS-T (PBS, pH 7.4, 0.1% Tween™-20) and then six times with PBS. Bound phages were eluted and propagated using standard phage recovery procedures. The second round of antibody phage display selection was performed as above, except mouse PD-L1-rCd4-His (SEQ ID NO: 81) was used to coat the Nunc immunosorb tubes, rCd4-His was used instead of Fc-His for deselection, and the output phage from the first round selected against human PD-L1-Fc-His was used as the input phage population. The third round with human PD-L1-Fc-His was performed exactly like the first round.

[0226] 1.2.3 Chain shuffling and solution phase selection The selected variable heavy (VH) anti-PD-L1 antibody population was shuffled with a naive variable light (VL) antibody population as described in Dyson et al., 2011, and this shuffled and rescued antibody phage display population was used in solution phase selections. Briefly, panning was performed in the first, second, and third rounds with human PD-L1-rCd4-His (SEQ ID NO: 79) (10 nM), human PD-L1-rCd4-His (SEQ ID NO: 79) (200 pM) and mouse PD-L1-rCd4-His (SEQ ID NO: 81) (10 nM), respectively, which resulted in an output anti-PD-L1 scFv population referred to as "selection 280". This scFv population contained human and mouse anti-PD-L1 binding scFvs and showed minimal cross-reactivity with human PD1 or rCd4 or the Fc tag, as determined by phage polyclonal ELISA performed as described in Dyson et al., 2011.

[0227] 1.3 Screening: ELISA, recombinant blocking assays, cell-based blocking assays 1.3.1 Monoclonal scFv ELISA The selected 280 scFv population from Example 1.2.3 was screened by ELISA to identify clones with the best binding to human PD-L1. The scFv population was subcloned into the soluble scFv vector pSANG10 and E. coli cultures containing soluble scFv were prepared as described (Martin et al., 2006; Studier, 2005). The soluble scFv were then used in a monoclonal ELISA with immobilized human PD-L1-rCd4-His (SEQ ID NO: 79). Briefly, Nunc Maxisorp plates (Thermo Fisher Scientific, 437111) were coated overnight with human PD-L1-rCd4-His (SEQ ID NO: 79) (5μg / ml, PBS), blocked with 2% MPBS for 1 hour, E. coli culture supernatant (diluted 1:2 in 2x2% MPBS) was added, and scFv was allowed to bind for 1 hour at room temperature. Bound scFv was detected with europium-labeled anti-FLAG M2 antibody (Sigma, F1804). A total of 470 clones were screened, which identified 346 anti-PD-L1 clones with binding signals for PD-L1 at least 10-fold higher than background compared to "empty" blocked wells that did not contain antigen. The 192 best anti-human PD-L1 clones, as assessed by primary ELISA signals, were selected for further analysis.

[0228] 1.3.2 Screening of scFvs in an ELISA-based PD-L1 / PD-1 blocking assay To identify clones that blocked the interaction between PD-L1 and PD1, ELISA was performed to screen for blocking scFv. Briefly, Nunc Maxisorp plates (437111, Thermo Fisher Scientific) were coated with anti-rCd4 (domains 3 and 4) antibody (MCA1022, OX-68, Bio-Rad) overnight, blocked with 3% MPBS, and incubated with human PD1-rCd4-His (SEQ ID NO: 79) (5 μg / ml in 3% MPBS) at room temperature for 1 hour. Biotinylated human PD-L1-Fc-His (SEQ ID NO: 79) (50 μl, 0.2 nM) was premixed with E. coli culture supernatant containing scFv. Nunc 96-well plates were washed 3 times with PBS, 0.1% Tween™-20 (PBS-T) and 3 times with PBS, after which the human PD-L1-Fc-His / scFv mix was added and incubated for 1 hour at room temperature. Plates were washed and bound human PD-L1-Fc-His was detected using goat anti-Fc-biotin (Jackson ImmunoResearch, 109-065-098, Laboratories, 0.1μg / ml, 3% MPBS) and Streptavidin-Europium (Perkin Elmer, 1244-360), followed by DELFIA Enhancement Solution (Perkin Elmer, 4001-0010). Of the 192 clones screened, 183 showed at least 90% blocking activity compared to the medium control. The 183 anti-PD-L1 scFv clones identified were further screened for mouse PD-L1 cross-reactivity in a primary ELISA as described in Example 1.3.1, but using immobilized mouse PD-L1-rCD4-His instead of human PD-L1. This identified 50 mouse cross-reactive anti-PD-L1 clones that were candidates for conversion to an IgG1 format.

[0229] 1.3.3 Conversion of blocking anti-PD-L1 scFv clones into IgG1 format Anti-PD-L1 scFv clones that blocked the interaction between PD-L1 and PD1 were converted to IgG1 format by subcloning the VL and VH genes into the IgG1 expression plasmid pINT3-IgG1 and expressed in HEK293 at a 4 ml scale as described in Chapple et al., 2006. Antibodies were batch affinity purified using Protein A Sepharose beads (PC-A100) and Proteus "1-Step Batch" Midi spin columns (Generon, GEN-1SB08) according to the manufacturer's instructions. Dialysis of purified antibodies was performed using GeBAflex maxi tubing with an 8 kDa cutoff (Generon, D045). If necessary, antibodies were concentrated to 2 μM by ultrafiltration.

[0230] 1.3.4 Screening for PD-L1 / PD-1 blocking activity in the Jurkat NFAT reporter co-culture assay The functional activity of the purified anti-PD-L1 mAbs was then assessed in a co-culture reporter assay screen. This screen was performed using GloResponse NFAT-luc2 / PD-1 stable Jurkat cell line (Promega, CS187102) and thawed and used PD-L1 cells (Promega, CS178103) according to the manufacturer's instructions. PD-L1 cells were seeded in HAM'S-F12 medium containing 10% FBS. The next day, PD-1 Jurkat reporter cells (Promega, CS187102) were resuspended in assay medium (90% RPMI1640, 1% FBS). Medium was removed from plates containing attached PD-L1 cells and 40μl of assay medium containing different antibodies at 2x concentration (200nM) was added to the attached cells followed by 40μl of the PD-1 cell mixture. Plates were incubated at 37℃ with 5% CO2 for 6 hours. BioGlo reagent (Promega, G7940, 80 μl) was added to each well and luciferase output was read using a BMG pherastar plate reader. This identified antibody G1 / 280_02_G02, capable of blocking the interaction of PD1 and PD-L1 in co-culture assays due to increased luciferase activity compared to no antibody controls. This activity was confirmed in a dose-response co-culture assay (doubling concentration range: 200 to 1.56 nM) and was calculated to be 50% effective at 50% EC 50 ) was 4.2 nM.

[0231] 1.4 Array Optimization Preliminary analysis of the G1 / 280_02_G02 antibody sequence identified a potential deamidation site in VH-CDR2, specifically an NG motif at Kabat positions 54 to 55. Because deamidation at this site could potentially affect binding, mutant clones were generated in which the NG motif was changed to either NA, NS, SG, or GG. These modifications did not result in a significant decrease in affinity for recombinant PD-L1 or potency of PD-L1 blocking activity, and a mutant clone containing the NS modification, designated G1 / 280_02_G02_NS, was selected for use in light chain shuffling.

[0232] 1.5 Overview of Naive Selection The phage selection strategy used identified over 50 anti-human PD-L1 binding clones with potent in vitro PD-1 / PD-L1 blocking activity and mouse PD-L1 cross-reactivity. Notably, G1 / 280_02_G02 showed strong activation in a cell-based PD-L1 reporter assay and was therefore selected for further optimization.

[0233] Example 2: Chain shuffling to generate anti-PD-L1 clones containing kappa light chains The G1 / 280_02_G02_NS antibody has a lambda light chain. As most monoclonal antibodies used in clinical settings to date have a kappa light chain (Jain et al., 2017), it was desired to use a chain shuffling campaign to generate clones containing the heavy chain of the G1 / 280_02_G02_NS antibody but paired with a kappa light chain that retained affinity for human PD-L1 and mouse cross-reactivity. A light chain shuffled library of scFv clones containing the heavy chain of the G1 / 280_02_G02_NS antibody combined with light chain variants was prepared using the IONTAS™ kappa light chain library in the phage display plasmid pIONTAS-1 (kappa library).

[0234] 2.1 Phage selection and screening strategies A number of phage display solutions were selected in three rounds using biotinylated human PD-L1-rCD4-His (SEQ ID NO: 79) and mouse PD-L1-rCD4-His antigen (SEQ ID NO: 81). Selections were performed by decreasing antigen concentrations in every round (varying from 100 to 0.02 nM) and a "no antigen" control was used in each round of selection. Selection details are shown in Table 2.

[0235] [Table 2]

[0236] Six selection outputs, two from round 2 (no. 871 and 872) and four from round 3 (no. 887, 890, 891 and 894), were selected for screening using the soluble scFv expression system as described in section 1.3.1. A total of 1692 soluble scFv clones were screened for binding to immobilized antigen by ELISA (hu-PD-L1-rCD4-His (SEQ ID NO: 79) antigen was coated onto Maxisorb plates at 3μg / mL in 50μl Dulbecco's PBS) using the assay described in Example 1.3.1 above using DELFIA enhancement solution.

[0237] Of the 1692 clones screened, 1029 clones produced signals over 2000 RFU in the DELFIA assay, with a success rate of approximately 61%. The top 736 clones were then selected and analyzed using a secondary assay (affinity ranking) with three concentrations of hPD-L1-rCD4-His antigen (1.0 nM, 0.2 nM, and 0.04 nM). From the 736 clones screened, 48 clones that showed the highest signals were selected for cloning and expression in IgG1 format. The clones were expressed in Expi293F™ (Fisher Scientific Catalog No. 13479756) cells at an 800 μl scale, and the culture supernatants were harvested 5 days post-transfection for further screening in IgG1 format.

[0238] 2.2 SPR screening All 48 antibodies were ranked by affinity using SPR (Biacore T200 instrument). For ranking, diluted supernatants (1:10 in running buffer made of 1X PBS and 0.002% Tween™-20) were immobilized on a Protein A chip (GE healthcare, product code: 29127556) and flowed over the surface prepared with human PD-L1-rCD4-His (SEQ ID NO: 79) at a concentration of 50 nM. The binding (k a ) and dissociation (k d ) rate constant to estimate the dissociation constant (K D The K D Values ​​were compared to that of clone 280_02_G02_NS in an Ig1 format (G1 / 280_02_G02_NS). Ten clones with unique sequences were identified that showed higher affinity for human PD-L1 than clone G1 / 280_02_G02_NS and therefore were subjected to full kinetic analysis together with clone G1 / 280_02_G02_NS.

[0239] Briefly, SPR experiments were performed using a BIAcoreT200 instrument. Antibodies from diluted culture supernatants were captured onto a Protein A chip (GE Healthcare, 29127556) on FC2 at a flow rate of 10 μl / min with a contact time of 60 seconds. Typically, this captures 500-800 RU of antibody. Two-fold dilutions of PD-L1-rCd4-His ranging from 50 to 0.05 nM were injected at flow rates of 50 nM to 30 μl / min on FC1 and FC2 (concentration range: 50 nM-0.05 nM). Binding was measured over 180 seconds and dissociation was measured over 300 seconds. All measurements were performed in PBS, pH 7.4, 0.05% Tween™-20 at 25°C. Kinetic parameters were determined by subtraction of reference cells and fitting of sensogram experimental data assuming a 1:1 interaction using BIAevaluation software (GE, BR-1005-97). The obtained data were fitted using the BIAevaluation software and the corresponding k a , kd , and K D Of the 10 clones tested, four antibodies, designated "G1 / 887_04_E12," "894_08_A05," "G1 / 894_08_E05," and "G1 / 887_04_G12," had subnanomolar K D This shows the value of K for G1 / 280_02_G02_NS. D The affinity data obtained under the described screening conditions showed that by kappa light chain shuffling as described in Example 2, the heavy chain of the G1 / 280_02_G02_NS antibody was paired not only with a lambda light chain but also with a kappa light chain to generate an antibody with good, and indeed improved, affinity for recombinant human PD-L1. The exact affinities generated at low levels of capture mAb are reported in Table 3, section 3.2.

[0240] Example 3: Characterization of kappa clones in IgG1 format 3.1 Cell-based PD-1 / PD-L1 blocking assay The ability of anti-PD-L1 clones containing kappa light chain, G1 / 887_04_E12, G1 / 894_08_E05 and G1 / 887_04_G12, to block the interaction between PD1 and PD-L1 was assessed in a bioluminescent cell-based assay using the PD1 / PD-L1 Blockade Bioassay product (Promega, J1250 / J1255) according to the manufacturer's recommendations. Blocking activity was compared to the G1 / 280_02_G02_NS clone.

[0241] Briefly, all antibodies were expressed and purified as described in section 1.3.3 and tested in duplicate at 3-fold dilutions ranging from 100 nM to 35 pM (8 concentrations). Calculated IC 50The values ​​are shown in Table 3. All clones tested were shown to be potent inhibitors of the PD1 / PD-L1 interaction, with clones G1 / 887_04_E12, G1 / 894_08_E05, and G1 / 884_04_G12, which contain three kappa light chains, showing even better IC than clone G1 / 280_02_G02_NS, which contains a lambda light chain. 50 The values ​​were shown.

[0242] [Table 3]

[0243] 3.2 Affinity The binding of anti-PD-L1 mAbs G1 / 887_04_E12, G1 / 887_04_G12, and G1 / 894_08_E05 to recombinant human biotinylated human PD-L1-Avi-His (Acro Biosystems, PD1-H82E5), cynomolgus monkey PD-L1-His (Acro Biosystems, PD1-C52H4), and mouse PD-L1-His (Acro Biosystems, PD1-M5220) was measured by SPR using a Biacore T200 instrument (GE Healthcare). Affinity was compared to the 280_02_G02_NS clone in IgG1 format (G1AA / 280_02_G02_NS; the "AA" in this clone name indicates that this clone also contained the "LALA" mutation in the CH2 domain).

[0244] Briefly, anti-PD-L1 mAb diluted to 2μg / ml in HBS-EP buffer (GE Healthcare, BR100188) was injected individually into flow cells 2, 3, and 4 of a Protein A chip (GE Healthcare, 29127556) at 30μl / min to achieve a final response of approximately 110RU. Recombinant human, cynomolgus monkey, and mouse PD-L1-His antigens diluted in HBS-EP buffer were injected three-fold at concentrations ranging from 81nM to 0.037nM into flow cells 1, 2, 3, or 4 as appropriate at 75μl / min for 4 minutes, followed by dissociation in buffer for 10 minutes. Regeneration was achieved by injecting 10mM glycine-HCL pH1.5 (GE Healthcare, Human Antibody Capture Kit, BR00356) at a rate of 30μl / min for 30 seconds. Subtracted data (flow cell 2-flow cell 1, flow cell 3-flow cell 1, or flow cell 4-flow cell 1) were analyzed using BIAevaluation 3.2 software (GE Healthcare) to identify binding using model 1:1 binding with mass transfer at a refractive index (RI) constant of 0. To determine the affinity of the mouse PD-L1 binding curves, the Rmax of the corresponding human binding profile was used.

[0245] Binding data showed that the G1AA / 280_02_G02_NS clone and the G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 clones bound to human and cynomolgus PD-L1 with low single-digit nanomolar or subnanomolar affinities, with full human / cynomolgus cross-reactivity (Table 4). Compared to the G1AA / 280_02_G02_NS clone, the binding affinities of the G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 clones were approximately 1.8-4.8-fold higher for human PD-L1 and 2.7-4.7-fold higher for cynomolgus PD-L1. The affinity of the clones for recombinant mouse PD-L1 was low, with K DValues ​​ranged from 38 to 225 nM, with the highest affinity observed for the G1 / 887_04_E12 clone. These data indicate that the heavy chain of the G1AA / 280_02_G02_NS antibody can be paired with both lambda and kappa light chains to generate an antibody with good (and subnanomolar in the case of kappa light chain pairing) affinity for recombinant human and cynomolgus PD-L1, and at least some affinity for recombinant mouse PD-L1.

[0246] [Table 4]

[0247] 3.3 Binding of anti-PD-L1 mAb to cell-expressed PD-L1 3.3.1 Generation of cells overexpressing human PD-L1 To assess the binding of anti-PD-L1 mAbs G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 to cell surface PD-L1, HEK293 cells overexpressing human PD-L1 were generated.

[0248] The human PD-L1 sequence (SEQ ID NO:83) was subcloned into the pcDNA™5 / FRT vector (ThermoFisher Scientific, Cat. No. V601020) using the KpnI and NotI restriction sites and the vector was then transformed into the Flp-In T-REx 293 cell line (Life Technologies, R780-07) using Lipofectamine 2000 (Life Technologies, 11668-019). Cells were grown in DMEM containing 10% FBS, 100μg / ml hygromycin B (Melford Laboratories Ltd, Z2475) and 15μg / ml blasticidin (Melford Laboratories Ltd, B1105) for 3-4 weeks until colonies of stably transformed cells formed. These colonies were expanded in the presence of 1 μg / ml doxycycline (Sigma Aldrich, D9891) and tested for PD-L1 expression using a PE-conjugated anti-human PD-L1 (MIH1) antibody (BD Biosciences, 557924). Cells were detached using cell dissociation buffer, washed once with PBS, and plated at 2 × 10 5 Cells were plated and incubated with antibodies diluted 1:20 in PBS for 1 h at 4°C, then washed again with PBS and measured using an Accur iC6 cytometer (BD Biosciences). Data were analyzed using FlowJoX software. Human PD-L1 expression was detected in the cell lines.

[0249] 3.3.2 Cell binding assay: Cell binding to HEK293-hPD-L1 and control HEK-FRT demonstrates specific binding. The anti-human PD-L1 mAbs, G1 / 894_08_E05, G1 / 887_04_E12 and G1 / 887_04_G12, were then tested for binding to HEK293 cells expressing human PD-L1 using flow cytometry. Non-specific binding was also assessed by testing binding to the parental HEK293 cells lacking human PD-L1 (Flp-In T-Rex 293 cell line, Life Technologies, R780-07).

[0250] HEK293 and HEK293.hPD-L1 suspensions were prepared in PBS containing 0.5% BSA (Sigma, A7906) and 1 × 10 5 Cells were washed once with 100 μl 1×DPBS and mAbs G1 / 894_08_E05, G1 / 887_04_E12 and G1 / 887_04_G12 were diluted (1.10) in 100 μl 1×DPBS (Gibco, 14190-094). -6 ~0.013 nM, 5-fold dilution). Washed cells were resuspended in the diluted antibody mix and incubated for 30 min at 4 °C, followed by one wash with PBS. Then, 100 μl / well of secondary antibody (Alexa Fluor 647-AffiniPure Goat Anti-Human IgG, F(ab')2 Fragment Specific, Stratech Scientific, 109-605-006-JIR) diluted 1:1000 in PBS was added, and the cell / antibody mix was incubated for 20 min at 4 °C, after which the cells were washed again with PBS and resuspended in 100 μl of PBS containing 7AAD (1:1000, Biotium, 40043) before analysis using a CantoII flow cytometer (BD Bioscience). Dead cells were excluded, and fluorescence was measured in the FITC channel (488 nm / 530 / 30). Geometric mean fluorescence intensity (GMFI) values ​​were plotted against the log concentration of antibody and the resulting curves were fitted using the log(agonist) vs response equation in GraphPad Prism.

[0251] G1 / 894_08_E05, G1 / 887_04_E12 and G1 / 887_04_G12 clones were EC 50 All mAb clones tested were found to bind to cell surface human PD-L1 with binding values ​​ranging from 0.26 to 0.29 nM (see Table 5). No binding to parental HEK293 cells was observed, indicating specificity of binding. Thus, all mAb clones tested bound specifically to PD-L1 with no non-specific binding observed.

[0252] [Table 5]

[0253] 3.4 Activity of anti-PD-L1 mAbs in mixed lymphocyte reaction assays The activity of anti-PD-L1 mAbs was tested in a mixed lymphocyte reaction (MLR) assay. The MLR assay measures the cellular immune response that occurs between two allogeneic lymphocyte populations (same species, but genetically distinct). The assay uses CD4+ T cells from one donor and monocyte-derived dendritic cells (iDCs) from another donor. Because immune cells contain physiological levels of immune checkpoint regulators, the MLR assay can be used to confirm that T cell activation is enhanced by the mAb in a human system.

[0254] 3.4.1 Generation of expanded CD4+ T cells PBMCs were isolated from leukocyte cones by Ficoll gradient separation. CD4+ T cells were isolated using the Human CD4+ T Cell Isolation Kit (Miltenyi Biotec Ltd, 130-096-533) according to the manufacturer's instructions. Human T-activator CD3 / CD28 Dynabeads (Life Technologies, 11131D) were resuspended by vortexing. The beads were transferred to a sterile 15 ml tube and the Dynabeads were washed by adding 10 ml RPMI (Life Technologies, 61870044) containing 10% FBS (Life Technologies, 10270106) and 1x penicillin streptomycin (Life Technologies, 15140122). The supernatant was discarded. 1.0x10 cells were cultured in RPMI supplemented with 10% FBS and 1x penicillin streptomycin solution. 6 CD4+ T cells at 1000 cells / ml and 50 IU / ml recombinant human IL2 (Peprotech, 200-02-50 μg) with a 3:1 bead-to-cell ratio were transferred to a T75 flask (Greiner Bio-one, 690195) and incubated at 37 °C + 5% CO2. After 3 days, cells were gently resuspended and counted. Cell density was adjusted to 0.8–1 × 10 by adding fresh medium (RPMI-10% FBS + Penicillin-Streptomycin solution 1X + 50 IU / ml rhuIL2) as needed. 6 On day 7 or 8, the CD3 / 28 beads were removed and the CD4+ T cells were repopulated at 1 × 10 6 cells / ml and incubated overnight. Cells were frozen and stored until needed.

[0255] 3.4.2 Generation of iDC Naive monocytes were isolated from human PBMCs using the Human Pan Monocyte Isolation Kit (Miltenyi Biotec Ltd, 130-096-537) according to the manufacturer's instructions. Monocytes were differentiated into iDCs using Human Mo-DC Differentiation Medium (Miltenyi Biotec Ltd, 130-094-812) according to the manufacturer's instructions.

[0256] 3.4.3 MLR assay Expanded T cells were thawed 1 day before the experiment, washed with AIM V medium (GIBCO, 12055-091), and incubated overnight in AIM V medium at 37°C, 5% CO2. Anti-human PD-L1 mAbs, G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12, were diluted in triplicate at 4x the final concentration in 50μl AIM V medium in a 96-well round-bottom plate (VWR, 734-1797). An anti-FITC antibody designated 4420 containing the LALA mutation (Bedzyk et al., 1989; Bedzyk et al., 1990) was included as a negative control. A 3-fold dilution series from 30nM to 0.002nM was tested. 1x10 mAbs suspended in 50μl AIM V medium were diluted in triplicate at 4x the final concentration. 4 iDC cells and 1 x 10 suspended in 100 μl of AIM V medium 5Both expanded CD4+ T cells were added to antibody diluent and incubated at 37°C + 5% CO2 for 5 days. The following controls were included: CD4+ T cells alone, iDCs alone, CD4+ T cells + iDCs, and AIMV medium alone. Supernatants were collected, samples were diluted (1:25) and interferon gamma (IFN-γ) concentrations were measured using a human IFN gamma ELISA Ready-SET-Go! kit (Life Technologies, 88-7316-77). Plates were read at 450 nm using a plate reader with Gen5 software, BioTek. Absorbance values ​​at 630 nm were subtracted from absorbance values ​​at 450 nm (corrected). Standard curves for calculating cytokine concentrations were based on a 4-parameter logistic curve fit (Gen5 Software, BioTek). Concentrations of human IFN-γ were plotted against the log concentration of antibody and the resulting curves were fitted using the log(agonist) vs. response equation in GraphPad Prism.

[0257] Anti-human PD-L1 mAbs G1 / 894_08_E05, G1 / 887_04_E12 and G1 / 887_04_G12 were used in EC 50 value is less than 0.030 nM, and IFN-γ (E max ) showed potent activity in the MLR assay with maximal levels exceeding 10,000 pg / ml (Table 6, representative Figure 1). 50 indicates the concentration of mAb at which half of the response is achieved, while E max are absolute values ​​indicating the maximum concentration of IFN-γ achieved in the assay. As expected, no activity was observed with the negative control G1AA / 4420 mAb.

[0258] [Table 6]

[0259] 3.5 Activity of anti-PD-L1 mAbs in the mouse DO11.10 T cell activation assay Anti-human PD-L1 mAbs G1 / 887_04_E12, G1 / 887_4_G12 and G1 / 894_08_E05 were shown to exhibit weak cross-reactivity to mouse PD-L1 (see Example 3.2, Table 4), so their functional activity against mouse PD-L1 was investigated in an interleukin-2 (IL-2) release assay based on DO11.10 OVA T-lymphocyte and LK35.2 B-lymphocyte hybridoma cell lines. IL-2 release is a marker of T cell activation. T cells expressing endogenous mouse PD-1 were transfected with an empty vector (pLVX). B-cells were transfected with mouse PD-L1 constructs.

[0260] 3.5.1 Generation of T cell lines using empty vectors DO11.10 cells (National Jewish Health) containing the empty lentiviral vector pLVX were generated using the Lenti-X HTX packaging system (Clontech, 631249) using lentiviral transduction. Virus was generated by co-transfecting the Lenti-X expression vector (pLVX) (Clontech, 631253) with the Lenti-X HTX packaging mix into the Lenti-X293T cell line (Clontech, 632180). DO11.10 cell line was transduced using lentiviral particles produced with the Lenti-X HTX packaging system.

[0261] 3.5.2 Generation of antigen-presenting cells that overexpress PD-L1 Lenti-X HTX packaging system (Clontech, 631249) was used to generate LK35.2 B cell lymphoma cells (ATCC, HB-98) overexpressing mouse PD-L1 using lentiviral transduction. Lenti-X expression vector (pLVX) (Clontech, 631253) containing mouse PD-L1 cDNA (encoding mouse PD-L1 of SEQ ID NO: 84) was co-transfected with Lenti-XHTX packaging mix into Lenti-X293T cell line (Clontech, 632180) to generate virus. LK35.2 cell line was transduced using lentiviral vector generated with Lenti-X HTX packaging system.

[0262] 3.5.3 Mouse DO11.10 T cell activation assay Dilutions of anti-PD-L1 mAbs G1 / 887_04_E12, G1 / 887_04_G12 and G1 / 894_08_E05 or anti-FITC negative control mAb (G1AA / 4420) were prepared in experimental medium (DMEM (Gibco, 61965-026), 10% FBS (Gibco, 10270-106), 1 mM sodium pyruvate (Gibco, 11360-070)). The mAbs were incubated at 4 × 10 in the presence of 2.46 μM OVA peptide (H-ISQAVHAAHAEINEAGR-OH, Pepscan) (100 μL LK35.2mPD-L1 cells (B cell hybridoma transduced with lentiviral vector containing mPD-L1 to overexpress mouse PD-L1) / mAb mixture per well of a 96-well round-bottom plate). 5 2 × 10 per ml in a 100 μl volume of experimental medium were mixed 1:1 with LK35.2mPD-L1 cells in experimental medium and incubated at 37 °C, 5% CO for 1 h. 5DO11.10 pLVX cells (DO11.10 T cell hybridoma transduced with empty lentiviral vector) were added to 100 μl of LK35.2mPD-L1 / (mAbs) mixture. Cells were then mixed and incubated at 37°C, 5% CO2 for 24 hours. Supernatants were collected and assayed with Mouse IL-2 ELISA kit (eBioscience, 88-7024-88 or R&D Systems, SM2000) according to the manufacturer's instructions. Plates were read at 450 nm using a plate reader with Gen5 software, BioTek. Absorbance values ​​at 570 nm were subtracted from absorbance values ​​at 450 nm (corrected). Standard curves for calculating cytokine concentrations were based on a four-parameter logistic curve fit (Gen5 Software, BioTek). The concentration of mouse IL-2 was plotted against the log concentration of mAb, and the resulting curves were fitted using the log(agonist) vs. response equation in GraphPad Prism.

[0263] The results are shown in Figure 2 and Table 7. The anti-human PD-L1 mAbs showed significant activity in the mouse T cell activation assay and potency (EC 50 ) ranged from 1 to 4.4 nM. As expected, no activity was observed with the negative control mAb. Of the three clones tested, G1 / 887_04_E12, which showed the highest affinity for recombinant mouse PD-L1 (see Table 4), was also the most potent clone in the T cell activation assay. The difference in potency was lower than the measured affinity, which is likely due to overexpression of mouse PD-L1 on LK35.2 cells in this assay.

[0264] [Table 7]

[0265] 3.6 Pharmacokinetics in naive mice To investigate the in vivo pharmacokinetics (PK), the anti-PD-L1 mAbs G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 were tested in an investigational grade PK study in which the mAbs were administered to non-tumor bearing mice and serum concentrations were measured over time.

[0266] C57 / BL6 mice (female, 9-10 weeks old) were divided into four groups of three animals and received a single dose of test antibody administered intravenously. Animals were administered one dose of 8 mg / kg anti-PD-L1 mAb. Antibodies were administered intravenously (100 μl, tail vein) and blood samples (20 μl, tail vein) were collected from three mice per time point at seven different time points. The time points were 0.5, 1, 6, 24, 48, 96, and 144 hours post-dose. Blood was allowed to clot for 2 hours at room temperature and spun at 2000 g for 20 minutes in a centrifuge before serum was collected and stored at -80°C. For analysis, all serum samples were thawed and run simultaneously on a Gyrolab xPlore instrument (Gyrolab Technologies) using the 200-3W-002-A program. Biotinylated goat anti-human IgG-heavy and light chain monkey adsorbents (Cambridge Bioscience, A80-319B) were used as capture reagents, and goat anti-human IgG-AF647 (Cambridge Bioscience, 2040-31) was used as detection reagent. The concentration of human IgG was measured in each serum sample, and the actual drug concentration was calculated based on the titration curve of each compound to eliminate potential differences in detection. Additional standard curves were run to verify that binding to capture or detection anti-human IgG mAbs was not altered by mAb.

[0267] The anti-PD-L1 mAb did not show an initial rapid clearance and exposure levels remained above 24 μg / ml for 6 days (Figure 3), as expected for the mAb and consistent with published anti-PD-L1 mAb data (Deng et al., 2016).

[0268] 3.7 Overview of characterization of kappa clones in IgG1 format The selected kappa light chain-containing anti-PD-L1 mAbs G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 demonstrated cross-reactivity with cynomolgus and mouse PD-L1, specific binding to cell surface-expressed PD-L1, and higher affinity for recombinant human and cynomolgus PD-L1 than the lambda light chain-containing clone G1 / 280_02_G02. Anti-PD-L1 mAbs G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 were shown to be potent activators of human T cells in vitro, retained functional mouse cross-reactivity, and maintained satisfactory PK profiles in non-tumor bearing mice.

[0269] Example 4: Sequence optimization 4.1 Identification and removal of potential protein deamidation sites Analysis of the G1 / 280_02_G02_NS clone sequence identified the sequence NSNT (SEQ ID NO: 6) within the H-CDR2 loop (Kabat positions 54-57) as a potential deamidation site that could affect binding if deamidated. Because the heavy chain of this clone was retained in all kappa light chain-containing clones obtained by the chain shuffling campaign described in Example 2, this potential deamidation site was also present in clones G1 / 887_04_E12, G1 / 894_08_A05, G1 / 894_08_E05, and G1 / 887_4_G12. Using specific primers closest to the germline sequence, the NSNT (SEQ ID NO: 6) sequence was changed by site-directed mutagenesis to either GGST (SEQ ID NO: 7), SGGT (SEQ ID NO: 5) or SGNA (SEQ ID NO: 8) in the four kappa light chain-containing clones to produce the mutant clones identified in Table 8. As well as removing this potential deamidation site, the role of the proline residue at Kabat position 28 in the VH region of the G1 / 887_04_E12 clone, which was unintentionally introduced into the sequence of this antibody during kappa light chain shuffling, was also investigated by reverting it to a threonine residue contained in the G1 / 280_02_G02_NS clone. The parental and resulting mutant clones (all in IgG1 format) were transfected at 0.8 ml scale and culture supernatants harvested 5 days post-transfection were used to determine the affinity of the clones for human and cyno PD-L1-rCD4-His by SPR. Cyno PD-L1-rCD4-His was generated as described in Example 1.1. With the exception of the mutant clone derived from the G1 / 887_04_E12 clone, all mutant clones retained sub-nanomolar affinity for human and cyno PD-L1 compared to their respective parental clones (see Table 8).

[0270] [Table 8]

[0271] The significantly reduced affinity of G1 / 929_01_A01, G1 / 929_01_A02, and G1 / 929_01_A03 clones compared to the parent (G1 / 887_04_E12) was more likely due to the deletion of a proline in the VH region at Kabat position 28, rather than the presence of GGST (SEQ ID NO:7), SGGT (SEQ ID NO:5), and SGNA (SEQ ID NO:8) substitutions in H-CDR2. It was surprising that this proline residue in the G1 / 887_04_E12 clone appeared to be important for affinity to PD-L1. Mutants derived from the three parental clones G1 / 887_04_E12, G1 / 894_08_E05 and G1 / 887_04_G12 containing an SGGT (SEQ ID NO: 5) substitution in H-CDR2 (positions 54-57), namely clones G1 / 929_01_A02, G1 / 929_01_A08 and G1 / 929_01_A11, were selected for further characterization based on the fact that this SGGT (SEQ ID NO: 5) substitution most closely resembles the germline sequence.

[0272] Using site-directed mutagenesis, a potential deamidation site in the H-CDR2 loop of the G1 / 280_02_G02_NS clone (NSNT at Kabat positions 54 to 57 (SEQ ID NO: 6)) was also modified to SGGT (SEQ ID NO: 5). Furthermore, a further potential deamidation site (NS motif) identified at Kabat positions 31 to 32 in the CDR1 of the lambda light chain of this clone was modified to NY by mutating serine 32 (Kabat numbering) to tyrosine, as tyrosine is found at this position in several germline sequences such as IGLV2-8-01, IGLV2-8-02, IGLV2-8-03, IGLV2-11-01, IGLV2-11-02, IGLV2-11-03 and IGLV2-14-01, IGLV2-14-02, IGLV2-14-03, IGLV2-14-04. The combination of these modifications resulted in a lambda light chain-containing clone, G1 / lambdav3, which was also selected for further characterization.

[0273] Example 5: mAb / mAb 2 Characterization 5.1 mAb and mAb 2 Form cloning and clone production The threonine residue at Kabat position 28 in the VH region of the G1 / 929_01_A02 "SGGT" mutant clone identified in Example 4 was mutated to a proline as present at the same position in the parent clone G1 / 887_04_E12 with the aim of improving affinity for human and cynomolgus PD-L1. Transient expression in HEK293-6E cells and purification using a mAb Select SuRe protein A column was used to generate this modified mutant clone, as well as the other three "SGGT" mutant clones identified in Example 4 in the IgG1 format and LALA mutation (G1 / 929_01_A08, G1 / 929_01_A11, and G1 / lambdav3), allowing testing of functional activity in the absence of effector function. The resulting mAbs were designated G1AA / E12v2, G1AA / E05v2, G1AA / G12v2, and G1AA / lambdav3. The heavy and light chain sequences are shown in SEQ ID NO:47 and SEQ ID NO:48 for G1AA / E12v2, SEQ ID NO:49 and SEQ ID NO:50 for G1AA / G12v2, SEQ ID NO:51 and SEQ ID NO:52 for G1AA / E05v2, and SEQ ID NO:61 and SEQ ID NO:62 for G1AA / lambdav3, respectively.

[0274] The antigen-binding site based on the CDRs of a mAb is 2 The constant domains can be combined with Fcab (fragment crystallized antigen binding) portions generated to provide bispecific antibodies, termed bispecific antibodies.

[0275] The anti-PD-L1 antibodies of the invention were synthesized using anti-CD137 / anti-PD-L1 mAbs to test their specificity for human PD-L1. 2 The mAb was produced in the form 2is produced in an IgG1 LALA format with a heavy chain that has an anti-human CD137 binding site in the CH3 domain of the Fcab portion and a VH domain from the anti-PD-L1 mAb clones G1AA / E12v2, G1AA / E05v2, G1AA / G12v2 or G1AA / lambdav3. 2 The heavy chain was co-transfected with the corresponding light chain of an anti-PD-L1 mAb to generate 2 were produced by transient expression in HEK293-6E cells and purified using a mAb Select SuRe Protein A column to obtain clones FS22-172-003AA / E12v2, FS22-172-003AA / G12v2, FS22-172-003AA / E05v2 and FS22-172-003AA / lambdav3. The heavy and light chain sequences are shown in SEQ ID NO:85 and SEQ ID NO:86 for FS22-172-003AA / E12v2, SEQ ID NO:87 and SEQ ID NO:88 for FS22-172-003AA / G12v2, SEQ ID NO:89 and SEQ ID NO:90 for FS22-172-003AA / E05v2, and SEQ ID NO:91 and SEQ ID NO:92 for FS22-172-003AA / lambdav3, respectively.

[0276] 5.2 Affinity of mAbs to human and cynomolgus PD-L1 To determine whether the additional sequence modifications present in G1AA / lambdav3 (i.e., NSNT (SEQ ID NO: 6) to SGGT (SEQ ID NO: 5) in VH-CDR2, NS to NY in VL-CDR1, and LALA mutations) and the kappa light chain-containing mAbs G1AA / E12v2, G1AA / E05v2, and G1AA / G12v2 (i.e., the LALA mutation, and G1AA / E12v2 alone, Threonine to Proline at Kabat position 28 in the VH region), affected the binding kinetics, the affinity of these anti-PD-L1 mAbs for human and cynomolgus PD-L1 was determined, as described in Example 3.2. mAbs G1AA / lamdav3, G1AA / E05v2, G1AA / E12v2, and G1AA / G12v2 showed affinities for human and cynomolgus PD-L1 similar to those observed in Example 3.2 (Table 4) for mAbs G1AA / 280_02_G02_NS, G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12, and the mAbs and mAbs tested 2 It was demonstrated that the binding affinity of was not affected by modification of the potential deamination site or introduction of the LALA mutation. The G1AA / E12v2 mAb had the lowest K D values ​​were 0.21 nM for human PD-L1 and 0.37 nM for cynomolgus PD-L1.

[0277] The VH of G1AA / E12v2 differs from the VH of G1 / 929_01_A02 (Example 4, Table 8) by one residue: G1AA / E12v2 retains a proline at Kabat position 28, whereas G1 / 929_01_A02 retains a threonine at this position. G1 / 929_01_A02 showed more than 10-fold lower affinity for both human and cynomolgus PD-L1 when compared to G1AA / E12v2. This data indicates that the proline residue at position 28 (Kabat nomenclature) in the VH of clone G1AA / E12v2 is important for affinity for human and cynomolgus PD-L1.

[0278] [Table 9]

[0279] 5.3 Specificity of PD-L1 family members PD-L1 belongs to the B7 homology family of immune checkpoint regulators (Ni and Dong, 2017). 2 To analyze the specificity of the anti-PD-L1 Fab arms of clones FS22-172-003AA / lambdav3, FS22-172-003AA / E05v2, FS22-172-003AA / E12v2 and FS22-172-003AA G12v2, their ability to bind to closely related family members was tested using SPR. The aim was to bind mAbs to closely related antigens at a concentration of 1 μM. 2 However, it did demonstrate specificity by showing binding to the PD-L1 receptor at a concentration of 1 nM.

[0280] Flow cells on a CM5 chip were immobilized with approximately 1000 RU of either human PD-L2-Fc (R&D Biosystems, 1224-PL), CD80-Fc (R&D Biosystems, 140-B1), PD-1-His (R&D Biosystems, 8986-PD), B7-H3-His (F-star in-house production), PD-L1-Fc (R&D Biosystems, 156-B7) or PD-L1-His (Acrobiosystems, PD1-H83F3). Flow cell 1 was run as a blank immobilization. mAb 2 was diluted to 1 μM and 1 nM (GE Healthcare, product code BR100188) in 1x HBS-EP buffer and flowed over the chip for 3 min, then allowed to dissociate for 4 min. For regeneration, a 30 s injection of 10 mM glycine pH 1.5 was used. To demonstrate coating of each antigen, a positive control mAb was injected at 50-100 nM. Binding levels were determined at the end of the association phase and compared.

[0281] All mAbs tested 2The clones displayed a high level of specificity, with binding responses ranging from 105 RU to 570 RU detected at 1 nM for either human PD-L1-Fc or PD-L1-His, and four antigen-binding mAbs detected at 1 μM. 2 These results demonstrate that the specificity of the Fab arm for PD-L1 is maintained despite the modifications made to the CDRs to remove potential deamination sites, and that the introduction of the LALA mutation and the mAb 2 These results demonstrated that production of Fabs in this format was not affected by their binding to PD-L1.

[0282] 5.4 Activity of anti-human PD-L1 mAbs in the MLR The anti-PD-L1 mAbs G1AA / E05v2, G1AA / E12v2, and G1AA / G05v2 were tested in a mixed lymphocyte reaction (MLR) assay as described in Example 3.4. G1AA / 4420 was used as a negative control. The data are shown in Table 10 and Figure 4. The mAbs G1AA / E05v2, G1AA / E12v2, and G1AA / G12v2 had an EC 50 and potent activity in the MLR assay with maximal levels (Emax) of IFN-γ exceeding 600 pg / ml (Table 10, Figure 4. EC 50 , especially the Emax values, were significantly different from those described in Example 3.4. This difference is believed to be due to donor variability, as the response relies on an alloreaction between T cells from one donor and monocyte-derived dendritic cells from another donor. The potency of the anti-human PD-L1 mAbs, as well as the ranking of the clones in order of potency, was consistent with the data described in Example 3.4. As expected, no activity was observed for the negative control G1AA / 4420 mAb.

[0283] [Table 10]

[0284] 5.5 Expression, purification and analytical characterization of anti-PD-L1 mAbs mAbs G1AA / E05v2, G1AA / E12v2, and G1AA / G12v2 were produced on a lab scale and characterized by standard analytical methods of SEC and differential scanning calorimetry (DSC).

[0285] 5.5.1 Lab-scale expression and purification of anti-PD-L1 mAb DNA sequences encoding mAbs G1AA / E05v2, G1AA / E12v2, and G1AA / G12v2 were transfected into HEK293 6E (National Research Council Canada) cells using PEIpro (Polyplus, France). After 5 days, cell culture fluid was harvested and purified on MabSelect Protein-A prepacked columns (both GE Healthcare, Uppsala, Sweden) using an AKTAxpress instrument. The columns were equilibrated with 50 mM Tris, pH 7.0, 250 mM NaCl, and then loaded with the harvested cell culture fluid. The resin was washed using 50 mM Tris, pH 7.0, 250 mM NaCl, and the mAbs were subsequently eluted using a buffer with a pH below 3.5.

[0286] 5.5.2 Analysis by SE-UPLC Post-purification SE-UPLC was performed within 24 hours of purification to measure the proportion of monomer (material was stored at 4°C) using an Acquity H-Class Bio UPLC (Waters Corp, UK). An Acquity UPLC BEH200 SEC 1.7 mm column (4.6 x 150 mm) was used and the mobile phase consisted of 250 mM sodium phosphate, 100 mM L-arginine, pH 6.8. Quantification of monomer, low molecular weight and high molecular weight species was performed using Empower software (Waters Corp, UK).

[0287] 5.5.3 Thermal stability The melting temperatures (T m) was measured using a Microcal VP capillary differential scanning calorimeter (DSC). G1AA / lambdav3 was included to assess differences between kappa and lambda light chain containing mAbs. Samples were measured at a concentration of 0.2mg / ml in sample buffer. The scan rate was set at 60°C / h and data were collected between 35°C and 100°C. Data analysis was performed using Origin7.0 software. As the DSC peaks of Fab and CH3 overlapped, one value was reported.

[0288] [Table 11]

[0289] A summary of the results is shown in Table 11. Three mAbs: G1AA / E05v2, G1AA / E12v2, and G1AA / G12v2 showed good analytical characterization parameters. Monomer purity after Protein A was greater than 98%, and the thermal stability (Tm) of the Fab transition was confirmed at the high end of the transition typically reported for IgG1, with G1AA / E12v2 appearing to be the most thermally stable (Fab / CH3 T M = 81.4-84.1°C). The lambda light chain mAb G1AA / lambdav3 had a lower Tm than the three kappa light chain-containing mAbs.

[0290] References Bedzyk WD, Johnson LS, Riordan GS, Voss EW Jr. Comparison of variable region primary structures within an anti-fluorescein idiotype family. J. Biol. Chem. 264(3), 1565-69 (1989). Bedzyk WD, Weidner KM, Denzin LK, Johnson LS, Hardman KD, Pantoliano MW, Asel ED, Voss EW Jr. Immunological and structural characterization of a high affinity anti-fluorescein single-chain antibody. J Biol Chem. 265(30), 18615-20 (1990). Brown MH, Barclay AN. Expression of immunoglobulin and scavenger receptor superfamily domains as chimeric proteins with domains 3 and 4 of CD4 for ligand analysis. Protein Eng. 7(4), 515-21 (1994). Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113(16), 3716-25 (2009). Chapple SD, Crofts AM, Shadbolt SP, McCafferty J, Dyson MR. Multiplexed expression and screening for recombinant protein production in mammalian cells. BMC Biotechnol. 6:49 (2006). Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U.S.A. 107(9), 4275-80 (2010). Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, Chiu H, McBride J, Johnson C, Xin Y, Koeppen H, Leabman M and Iyer S. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs 8(3), 593-603 (2016). Dyson MR, Zheng Y, Zhang C, Colwill K, Pershad K, Kay BK, Pawson T, McCafferty J: Mapping protein interactions by combining antibody affinity maturation and mass spectrometry. Anal. Biochem. 417(1), 25-35 (2011). Grosso J, Inzunza D, Wu Q, Simon J, Singh P, Zhang X, Phillips T, Simmons P, Cogswell J. Programmed death-ligand 1 (PD-L1) expression in various tumor types. J. Immunother Cancer. 1(Suppl 1), 53 (2013). Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563-7 (2014). Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75(24), 12161-8 (2001). Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56(13), 3055-61 (1996). Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164(8), 4178-84 (2000). Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99(19), 12293-7 (2002). Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Baruah H, Gray LT, Krauland EM, Xu Y, Vasquez M and Wittrup KD. Biophysical properties of the clinical-stage antibody landscape. PNAS 114 (5), 944-949 (2017). Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of Proteins of Immunological Interest, 5th ed. NIH Publication No. 91-3242. Washington, D.C.: U.S. Department of Health and Human Services (1991). Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs 4(2),182-97 (2012). Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs. 8(6), 1010-20 (2016). Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 373(13), 1270-1 (2015). Lefranc MP, Pommie C, Kaas Q, Duprat E, Bosc N, Guiraudou D, Jean C, Ruiz M, Da Piedade I, Rouard M, Foulquier E, Thouvenin V, Lefranc G. IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. Dev. Comp. Immunol. 29(3), 185-203 (2005). Martin CD, Rojas G, Mitchell JN, Vincent KJ, Wu J, McCafferty J, Schofield DJ. A simple vector system to improve performance and utilisation of recombinant antibodies. BMC Biotechnol. 6, 46 (2006). Ni L, Dong C. New B7 family checkpoints in human cancers. Mol. Cancer Ther. 16(7), 1203-11 (2017). Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528), 558-62 (2014). Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M. Anti-PD-1 / PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int. J. Infect. Dis. 56, 221-228 (2017). Schofield DJ, Pope AR, Clementel V, Buckell J, Chapple SDj, Clarke KF, Conquer JS, Crofts AM, Crowther SR, Dyson MR, Flack G, Griffin GJ, Hooks Y, Howat WJ, Kolb-Kokocinski A, Kunze S, Martin CD, Maslen GL, Mitchell JN, O'Sullivan M, Perera RL, Roake W, Shadbolt SP, Vincent KJ, Warford A, Wilson WE, Xie J, Young JL, McCafferty J. Application of phage display to high throughput antibody generation and characterization. Genome Biol. 8(11), R254 (2007). Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol. 67(2 Pt A), 95-106 (2015). Studier FW. Protein production by auto-induction in high density shaking cultures. Protein Expr. Purif. 41(1), 207-34 (2005). Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 9(1), 63-73 (2018). Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-33 (2013). Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol. 18(2), 91-104 (2017).

[0291] Sequence Listing Information Antibody sequence Notes: i. The complete heavy chain, variable domain is shown in italics, CDRs according to the Kabat scheme are shown in italics and underlined, CDRs according to the IMGT scheme are shown in bold italics, therefore overlapping IMGT and Kabat CDR sequences are shown in bold, italics and underlined, and where applicable, the position of the LALA mutation is shown in bold and underlined. ii. The amino acid and cDNA sequences of the complete heavy chain are provided without the optional C-terminal lysine. iii. Complete light chain, variable domain is shown in italics, CDRs according to the Kabat scheme are shown in italics and underlined, CDRs according to the IMGT scheme are shown in bold italics, therefore overlapping IMGT and Kabat CDR sequences are shown in bold, italics and underlined. iv. In the amino acid sequences of the variable domains, CDRs according to the Kabat scheme are shown in italics and underlined, CDRs according to the IMGT scheme are shown in bold italics, therefore overlapping IMGT and Kabat CDR sequences are shown in bold, italics and underlined. v. CDR amino acid sequences according to both the Kabat and IMGT schemes are provided.

[0292] [Table 12]

[0293] [Table 13]

[0294] [Table 14]

[0295] [Table 15]

[0296] [Table 16]

[0297] [Table 17]

[0298] [Table 18]

[0299] [Table 19]

[0300]

Table 20

[0301]

Table 21

[0302]

Table 22

[0303]

Table 23

[0304]

Table 24

[0305]

Table 25

[0306]

Table 26

[0307]

Table 27

[0308]

Table 28

[0309]

Table 29

[0310]

Table 30

[0311]

Table 31

[0312]

Table 32

[0313]

Table 33

[0314]

Table 34

[0315]

Table 35

[0316]

Table 36

[0317]

Table 37

[0318]

Table 38

[0319]

Table 39

[0320]

Table 40

[0321]

Table 41

[0322]

Table 42

[0323]

Table 43

[0324]

Table 44

[0325]

Table 45

[0326]

Table 46

[0327]

Table 47

[0328]

Table 48

[0329]

Table 49

[0330]

Table 50

[0331]

Table 51

[0332]

Table 52

[0333]

Table 53

[0334]

Table 54

[0335]

Table 55

[0336]

Table 56

[0337]

Table 57

[0338]

Table 58

[0339]

Table 59

[0340]

Table 60

[0341]

Table 61

[0342]

Table 62

[0343]

Table 63

[0344]

Table 64

[0345]

Table 65

[0346]

Table 66

[0347]

Table 67

[0348]

Table 68

[0349]

Table 69

[0350]

Table 70

[0351]

Table 71

[0352] [Table 72]

[0353] [Table 73]

[0354] [Table 74]

[0355] [Table 75]

[0356] mAbs 2 mAbs tested in the format Notes: i. In the heavy chain sequence, the variable domains are in italics, and the position of the LALA mutation, if applicable, is bold and underlined. ii. In the light chain sequence, the variable domains are in italics.

[0357] [Table 76]

[0358] [Table 77]

[0359] [Table 78]

[0360] [Table 79]

[0361] [Table 80]

[0362]

Table 81

[0363]

Table 82

Claims

1. An antibody molecule or antigen-binding fragment thereof capable of specifically binding to PD-L1, the antibody molecule or antigen-binding fragment thereof comprising an antigen-binding site comprising the VH domain and the VL domain of antibody G1AA / E12v2 of SEQ ID NOs: 27 and 28, respectively.

2. The antibody molecule or antigen-binding fragment thereof described in claim 1, comprising the heavy chain and / or light chain of antibody G1AA / E12v2 of SEQ ID NOs: 47 and 48, respectively.

3. The antibody molecule or antigen-binding fragment thereof of claim 2, wherein the heavy chain of the antibody molecule or antigen-binding fragment thereof comprises an additional lysine residue (K) at the C-terminus of the CH3 domain sequence of the heavy chain.

4. (i) the antibody molecule or antigen-binding fragment is a multispecific molecule comprising at least a second antigen-binding site; and / or (ii) the antibody molecule or antigen-binding fragment thereof comprises a second antigen-binding site located in a constant domain of the antibody molecule or antigen-binding fragment; An antibody molecule or an antigen-binding fragment thereof according to any one of claims 1 to 3.

5. An antibody molecule or an antigen-binding fragment thereof described in claim 4, wherein the multispecific molecule comprising at least the second antigen-binding site is a bispecific molecule.

6. An antibody molecule or antigen-binding fragment thereof comprising the features according to claim 4 (ii), wherein the second antigen-binding site comprises: (a) a first sequence in the AB structural loop and / or a second sequence in the EF structural loop of a constant heavy chain domain; (b) a first sequence in the AB structural loop and a second sequence in the EF structural loop of a constant heavy domain; (c) a first sequence in the AB structural loop and / or a second sequence in the EF structural loop and / or a third sequence in the CD structural loop of a constant heavy chain domain; or (d) a first sequence in the AB structural loop, a second sequence in the EF structural loop, and a third sequence in the CD structural loop of the constant heavy domain; Including, An antibody molecule or an antigen-binding fragment thereof according to claim 4 or 5.

7. 7. An antibody molecule or an antigen-binding fragment thereof according to any one of claims 4 to 6, wherein the antibody molecule or antigen-binding fragment thereof has the features according to claim 4 (ii) and the constant domain is a CH3 domain.

8. (i) the antibody molecule is immunoglobulin G (IgG), or an antigen-binding fragment thereof; (ii) the antibody molecule is an IgG1 or a fragment thereof, or an IgG4 or a fragment thereof; or (iii) the antibody molecule is an IgG1 or a fragment thereof having a modified Fc region; An antibody molecule or an antigen-binding fragment thereof according to any one of claims 1 to 7.

9. The antibody molecule or antigen-binding fragment thereof has the features according to claim 8 (iii), (i) the antibody molecule is an IgG1 or a fragment thereof having a modified Fc region with reduced immune effector function; (ii) the modified Fc region has reduced ADCC and / or CDC compared to IgG1; and / or (iii) the modified Fc region comprises a LALA, LALA-PA, or LALA-PG modification; 9. An antibody molecule or an antigen-binding fragment thereof according to claim 8.

10. The antibody molecule or antigen-binding fragment thereof of claim 8 or 9, wherein the antibody molecule or antigen-binding fragment thereof has the features described in (iii) of claim 8, and the antibody molecule is an IgG1 or antigen-binding fragment thereof comprising a LALA modification in the Fc region.

11. The antibody molecule or antigen-binding fragment thereof comprises the features according to (i) or (ii) of claim 4 or claim 5, (i) the second antigen-binding site binds to an inhibitory checkpoint molecule, a costimulatory molecule, or a tumor-associated antigen; and / or (ii)(a) the second antigen-binding site does not bind to OX40, inducible T cell costimulator (ICOS), or CD137; (b) the second antigen-binding site does not bind to CD27 or glucocorticoid-induced TNFR-related protein (GITR); or (c) the second antigen-binding site does not bind to lymphocyte activation gene 3 (LAG-3); An antibody molecule or an antigen-binding fragment thereof according to any one of claims 4 to 10.

12. A conjugate or fusion comprising an antibody molecule or an antigen-binding fragment thereof according to any one of claims 1 to 11 and an immune system modulator (agonist or antagonist), a cytotoxic molecule, or a radioisotope.

13. A nucleic acid molecule or set of nucleic acid molecules encoding an antibody, antigen-binding fragment thereof, conjugate or fusion thereof according to any one of claims 1 to 12.

14. A nucleic acid molecule or set of nucleic acid molecules according to claim 13, comprising cDNA sequences encoding one or more of the VH and VL, Fab, heavy chain and / or light chain of the antibody G1AA / E12v2.

15. comprising a first nucleic acid sequence and a second nucleic acid sequence, The first nucleic acid sequence comprises a VH cDNA sequence encoding the VH of the antibody G1AA / E12v2 of SEQ ID NO: 27, and the second nucleic acid sequence comprises a VL cDNA sequence encoding the VL of the antibody G1AA / E12v2 of SEQ ID NO:

28. A nucleic acid molecule or a set of nucleic acid molecules according to claim 14.

16. 16. A vector or a set of vectors comprising a nucleic acid molecule or a set of nucleic acid molecules according to any one of claims 13 to 15.

17. A recombinant host cell comprising a nucleic acid molecule or set of nucleic acid molecules according to any one of claims 13 to 15, or a vector or set of vectors according to claim 16.

18. 17. A method for producing an antibody molecule or antigen-binding fragment thereof according to any one of claims 1 to 11, or a conjugate or fusion according to claim 12, comprising culturing a recombinant host cell of claim 17 under conditions suitable for the production of the antibody molecule, antigen-binding fragment, conjugate or fusion.

19. 20. The method of claim 18, further comprising isolating and / or purifying the antibody molecule, antigen-binding fragment, conjugate or fusion.

20. A composition comprising an antibody molecule or an antigen-binding fragment thereof according to any one of claims 1 to 11, or a conjugate or fusion according to claim 12, and an excipient.

21. 21. A pharmaceutical composition for therapeutic treatment of an individual, comprising an antibody molecule or an antigen-binding fragment thereof according to any one of claims 1 to 11, a conjugate or fusion according to claim 12, or a composition according to claim 20.

22. 22. The pharmaceutical composition of claim 21 for administration to an individual in combination with a second treatment.

23. 23. The pharmaceutical composition of claim 22, wherein the second treatment is radiation therapy.

24. The pharmaceutical composition of claim 23, wherein the radiation therapy is targeted radiation therapy.

25. A pharmaceutical composition for the diagnosis of an individual or for the diagnosis of an in vitro sample from an individual, comprising an antibody molecule or an antigen-binding fragment thereof according to any one of claims 1 to 11, a conjugate or fusion according to claim 12, or a composition according to claim 20.

26. 21. A diagnostic agent comprising an antibody molecule or an antigen-binding fragment thereof according to any one of claims 1 to 11, a conjugate or fusion according to claim 12, or a composition according to claim 20.

Images